211 108 38MB
English Pages 709 [712] Year 1986
Marker Proteins in Inflammation Volume 3
Marker Proteins in Inflammation Volume 3 Proceedings of the Third Symposium Lyon, France, June 26-28,1985 Editors J. Bienvenu • J. A. Grimaud • P Laurent
W DE G Walter de Gruyter • Berlin • New York 1986
Editors Jacques Bienvenu, M. D. Jean Alexis Grimaud, M. D. Philippe Laurent, M. D. Institut Pasteur de Lyon 77, Rue Pasteur F-69365 Lyon Cédex 07 France
CIP-Kurztitelaufnahme der Deutschen Bibliothek Marker proteins in inflammation : proceedings of the . . . symposium. Berlin ; New York : de Gruyter Vol. 3. Proceedings of the third symposium, Lyon, France, June 26-28,1985. 1986.-XVI, 693 p. ISBN 311010639 6
ISBN 311010639 6 Walter de Gruyter • Berlin • New York ISBN 0-89925-223-0 Walter de Gruyter, Inc., New York Copyright © 1986 by Walter de Gruyter & Co., Berlin 30. All rights reserved, including those of translation into foreign languages. No part of this book may be reproduced in any form - by photoprint, microfilm or any other means nor transmitted nor translated into a machine language without written permission from the publisher. Printing: Gerike GmbH, Berlin. - Binding: D. Mikolai, Berlin. - Printed in Germany.
P R E F A C E
The Third Symposium on Markers of Inflammation, held in Lyon in the l a s t week of June 1985, was an international meeting that brought together some 300 s c i e n t i s t s and physicians. During t h i s Symposium which was sponsored by the "Groupe d'Etude et de Recherche sur
les Marqueurs de 1'Inflammation - GERMI",
under i t s president Professor J.L. Touraine, the participants exchanged a l o t of new information about progress in the study of inflammation d i s o r d e r s . Recent discoveries about the fundamental aspects and the c l i n i c a l
relevance of chemi-
cal messengers that communicate between c e l l s of the lymphoid system, such as i n t e r l e u k i n s and lymphokins, have caused great excitement. The complex effects of the b i o l o g i c a l actions of INTERLEUKINS include most of the c l i n i c a l features of inflammation, such as swelling of t i s s u e s and j o i n t s , pain, fever, modulation of immune response, and also the breakdown, repair and remodelling of injured t i s s u e s . Speakers from several
countries
described the p u r i f i c a t i o n of i n t e r l e u k i n s . They reported on the cloning of genes by the new methods of molecular b i o l o g y , and discussed the opportunities for production by biotechnology and the potential applications to the t r e a t ment of disease. Basic and c l i n i c a l
research on several inflammatory diseases was reported, for
example a disease called AMYLOIDOSIS. In t h i s disease certain blood proteins suddenly increase in concentration. Sometimes, these proteins are deposited as f i b r i l s in t i s s u e s such as l i v e r , kidney and heart, and t h i s may eventually cause organ f a i l u r e . Methods to purify and measure these markers in the blood and t h e i r c l i n i c a l usefulness were presented. The second day emphasized the molecular pathology of CONNECTIVE TISSUE MATRIX. Connective t i s s u e c e l l s '
populations and extracel1ular components are involved
from the very beginning of the inflammatory process. Research devoted to ext r a c e l l u l a r matrix has accelerated greatly over the past ten years. The growing f e e l i n g that almost every aspect of matrix research can be p r o f i t a b l y studied at the c e l l u l a r level has promoted u l t r a s t r u c t u r a l tissual
i n v e s t i g a t i o n s and
immunolabelling in d i f f e r e n t experimental model and human diseases.
During t h i s same period, the physico-chemical studies of p a r t i c u l a r matrix
VI components came to i n t e r e s t greatly cell b i o l o g i s t s and pathologists t r y i n g to v i s u a l i z e what kind of micro-domain might surround c e l l s involved in i n flammatory processes. L i v e r , lung, pancreas, colon, dentin, c a r t i l a g e ,
...
are target organs for inflammation and f i b r o s i s . Studies on granulomas ( s c h i s t o s o m i a s i s offers an e x c i t i n g model) are now leading to new developments where e x t r a c e l l u l a r matrix changes must be considered as an important additional factor implicated in the natural history of t h e i r formation. Chronic i n flammatory i n f i l t r a t e s contain factors generated during the c e l l u l a r immune response producing collagen accumulation and/or f i b r o b l a s t and myofibroblast stimulation. Recent progress on the characterization and synthesis of these mediators has opened new perspectives on a possible control of post-inflammatory f i b r o s i s and led t h i s f i e l d of i n v e s t i g a t i o n into a mostly exciting phase. The l a s t day was devoted to the design of synthetic DRUGS that may prevent or a l l e v i a t e inflammatory conditions. The application of biological agents such as interferon and monoclonal antibodies in immunopathology was also discussed. One of the aims of GERMI meetings i s to bring together in a common e f f o r t s c i e n t i s t s and c l i n i c i a n s from d i f f e r e n t countries for an exchange of experience and to focus on advances in the study and treatment of both acute and chronic inflammatory diseases. This aim has been l a r g e l y reached when we cons i d e r that more than 80 papers appear in the present proceedings. The Editors wish to express t h e i r sincere gratitude to Professor Frank W. Putnam of the department of Molecular Biology and Biochemistry, Indiana University (Bloomington, Indiana, USA) who acted as an expert president of t h i s Symposium. We would l i k e to thank the Vice Presidents of the Symposium: Doctor J.T. Whicher ( B r i s t o l , U.K.) and Professor M. Perrin Fayolle (Lyon, France) whose knowledge of the topics was greatly appreciated. The following i n s t i t u t i o n s provided f i n a n c i a l support: GERMI, I n s t i t u t Pasteur de Lyon et du Sud E s t , Fondation Merieux, Société Française d'Immunologie, Hospices C i v i l s de Lyon, Biomërieux, Hyland-Travenol, Hoechst Behring, Orimbio, B i o l y o n , Rhone Poulenc, Beckman, Sebia, Diagnostica Merck, Corning Medical.
We wish to express our profound gratitude to the organizing committee of the Symposium for t h e i r outstanding e f f o r t . This includes Helene Bernon, Abel
VII R o u l l e t , Professor M. Carraz, and Professor J . L . Touraine. The publication of these proceedings was made possible by the collaboration of authors and the s t a f f of Walter de Gruyter. Lyon, January 1986
J. Bienvenu J.A. P.rimaud P. Laurent
C O N T E N T S I N T R O D U C T O R Y
L E C T U R E
Progress in plasma protein related to inf larrmation. F.W. Putnam S E C T I O N
I
I N T E R L E U K
INS
The biological effects of purified and recaitoinant hunan interleukin 1. Ch. A. Dinarello
17
Are there defects in the production of interleukin 1 in disease ? J.T. Whicher, C. Westacott.
27
Negative acute phase protein : an interleukin 1 independent mechanism ? A. Fleck, M.A. Myers, Vasantha Nagendran.
37
Prostacyclin production frcm vascular endothelium interleukin 1. J.J.F. Belch, D. Shapiro, A. Shenkin, R.D. Sturrock.
41
is
enhanced
by
Effects of drugs altering arachidonic acid metabolism on interleukin 1 release from monocyte-1ike cells. D. Shapiro, J.J.F. Belch, R.D. Sturrock, A. Shenkin.
43
Murabutide induced production of non pyrogenic interleukin 1 by hunan monocytes and rabbit macrophages. C. Damais, G. Riveau, M. Parant, L. Chedid.
47
Does protracted IL-1 production cause a depression of cell mediated imnunity ? Vasantha Nagendran, M.A. Myers, A. Fleck, M.S. Pulley, D.C. Dunonde. Stable E rosettes : marker of activated hunan T-lymphocytes. A. Gaspar, P. Laurent, J. Marichy.
59
Production, purification and biological activities of natural hunan interleukin 2. L. Rimsky, H. Wakasugi, P. Robin, J.F. Lagabrielle, I). Fradelizi, J. Bertoglio.
63
Interleukin 2 (IL2) production by lymphocytes of hunan breast cancer patients. R. Lidereau, J. Oglobine, J. Anione, M. Renaud, M. Martinière, M.H. Chámpeme, A. Desplaces.
77
Prothymocytes in mouse fetal liver produce interleukin 2. M. Romano, J. Zenmour, J.L. Touraine.
83
X S E C T I O N AMYLOID
II P R O T E I N S
I s o l a t i o n and physico-chemical c h a r a c t e r i s t i c s of hunan serun amyloid P component from normal and acute phase s e r a . L. M i r i b e l , P. Arnaud.
89
Serum amyloid P carponent evaluation. B.A. F i e d e l , C . S . L . Ku.
99
(SAP)
and
hemostasis
:
a
continuing
Mechanism of induction of synthesis of serun amyloid P carponent (SAP) by mouse hepatocytes in c u l t u r e . R . F . Mortensen. R e a c t i v i t y of hunan serun amyloid P p r o t e i n (SAP) with concanavalin A. A. Mackiewicz, S . Mackiewicz, J . A . K i n t , J . G . Leroy, I . Vandermeulen. A new binding s p e c i f i c i t y practical applications.
for
serim
amyloid
P
component
105
117
and i t s
D. Serban, Ch. Rordorf-Adam.
125
Structure and Ffunction of Serun Amyloid A protein (SAA). Benson, . E . Dwulet, B. Kluve-Beckerman, M.Aldo-Benson. M.D.
129
Serun Amyloid A protein (SAA) - a s e n s i t i v e inflanmation marker. G. Marhaug, M. Ostensen, G. Husby, A. Husebekk, K. S l e t t e n .
139
SAA as a marker of inflammatory d i s e a s e . R . E . Chambers, J . T . Whicher.
145
Clinical usefulness of SAA and disorders : a conparative study.
CRP measuranents
in
inf lamnatory
C . P . J . Maury.
153
Iirmunonephelcmetric SAA measurement H. Bernon, J . Bienvenu, P. Laurent, M. Peyret.
157
S E C T I O N OTHER
III
HUMAN
ACUTE
PHASE
P R O T E I N S
Does hunan C-Reactive Protein c i r c u l a t e in ccmplexed form ? Equilibrium chromatography and d i a l y s i s s t u d i e s . M. Pontet, J . P . T r e s c a , M. O l l i v i e r , R. Engler.
XI
Evaluation of a q u a n t i t a t i v e l a t e x assay f o r CRP determination by l a s e r nephelometry : r e s u l t s of a c o l l a b o r a t i v e study. F. D a t i , W. Kapmeyer, A. Adam, J . Bienvenu, R.L. Hunbel, W. M u l l e r .
169
Alpha 1 - a n t i t r y p s i n and haptoglobin in normal and a l l e r g i c responses. M.A. Santos Rosa, M.F. Gareào, A.J.A. Robalo Cordeiro, C. Guimaràes, F. Campilho, J . Fleming T o r r i n h a .
175
Hie molecular v a r i a n t s of alpha 1 - a c i d g l y c o p r o t e i n : study of the g l y c o s y l a t e d dimeric, polymeric, and albimin-corrplex forms. L. M i r i b e l , P. Arnaud.
183
Fibronectin fragments act as cryoprecipi t a t ion. J . C . Renversez, C. Revol, M.J. V a l l é .
195
promoters
of
inmunoglobul in
F i b r o n e c t i n level in amniotic f l u i d . A.M. Mangé, F. B e t t r a y , F. Muí 1er.
201
HieAdam, himan J kal 1 ikrein-kininogen A. . Damas, J . Lecomte. - system.
205
Protease a c t i v i t é s in the cytosol of b r e a s t t u n o r s . J . Oglobine, C. Bouchet, F. Spyratos, K. Hacène, Desplaces.
C.
Brault,
A.
Serim p r o t e i n p r o f i l e e v o l u t i o n during moderate m a l n u t r i t i o n . M. David, A. Lobera, E. Legrand. SECTION
IV
ANIMAL
ACUTE
PHASE
PROTEINS
Biochemical c h a r a c t e r i s t i c s of acute phase p r o t e i n s in the r a t . R. Engler, F. Mege.
231
Synthesis of two r a t acute phase r e a c t a n t s : alpha 1 - a c i d g l y c o p r o t e i n and C3 by hepatocytes c o - c u l t u r e d with a l i v e r e p i t h e l i a l c e l l . J . P . Lebreton, M. Oaveau, M. Hiron, M. Fontaine, D. G i l b e r t , D. Biou, Ch. Guguen-Guillouzo.
24 3
Effects of 17-beta-oestradiol, 17-alpha-ethyniloestradiol, 5 - a l p h a - d i h y d r o t e s t o s t e r o n e and t u r p e n t i n e - o i l on the s y n t h e s i s of C3 and alpha 1 - a c i d glycoprotein in the r a t . M. Daveau, M. Hiron, M. Fontaine, J . P . Lebreton, D. Biou. 247 Production of acute phase p r o t e i n s by hepatocytes maintained in co-culture. A. Guillouzo, F. D e l e r s , G. B a f f e t , R. Engler, C. Guguen-Guillouzo
253
XII
Biosynthesis and secretion of haptoglobin by chicken embryo hepatocyte primary culture. F. Delers, R. Engler. 261 The Brown Norway deficient rat as a tool for the study involvement of the kinin system in sane physiological processes. J. Damas, A. Adam. Transferrin and alpha 2-macroglobulin-I reactants in the mouse. P.M.H. Heegaard, T.C. Bog Hansen.
are
of the 26 5
circulating acute-phase 275
A comparative study on the physico-chemical properties of himan, rabbit and rat C-reactive protein and serum amyloid P-ccmponent. M. Ollivier, M. Pontet, R. Engler. S e n m amyloid P component in the assessment of arthritis activity in autoimmune MRL/lpr/lpr mice. C. Rordorf-Adam, D. Serban, A. Pataki. 2 97 Hie effects of different drugs upon the level of serun amyloid P carponent in autoimmine MRL lpr/lpr mice. C. Rordorf-Adam, D. Serban, M. Gruninger, B.F. Rordorf. 303
S E C T I O N
V
C O N N E C T I V E M A T R I X AND I N F L A M M A T O R Y P R O C E S S E S The extracellular matrix and the inflaimiatory process. J. Labat-Robert, L. Robert, W. Hornebeck.
311
Structure andW.E. function of D.M. connective tissue proteoglycans. J.R. Hassel, Horton, Noonan, K.J. Doege, G.W. Laurie.
327
Isolation and characterization of fibronectin from mouse plasma. G. Caillot, G. Picelli, D.J. Hartmann, G. Ville.
337
Type V collagen : heterogeneity in different tissues. J. Rauterberg, D. Troyer.
343
Type VI collagen and inflammation. R. Garrone, J. Tiollier.
357
Basement membranes and tumoral invasion in the manmary gland. C. Clavel, P. Birembaut, J.J. Adnet, J.M. Foidart.
363
Fibroblasts and fibrocytes. Ch. M. Lapiere.
369
Cytoskeletal and cytocontractile features of myofibroblasts. G. Gabbiani.
375
XIII Collagen metabolism in the aorta of spontaneously hypertensive rats : variations in enzyme activities according to blood pressure and age. C. Falcy, A. Grochulski, N. Gilson, A.M. Borsos, N. Christeff, J.P. Dupeyron, J. Peyroux, M. Sternberg, J. Far jane 1, A. Rat trier.
387
Collagen metabolism in the heart of spontaneously hypertensive rats : variations in enzyme activities at different ages. C. Falcy, N. Gilson, A.M. Borsos, N. Christeff, J.P. Dupeyron, J. Peyroux, M. Sternberg, A. Rattner, J. Farjanel. Cell-cell and cell-matrix interactions in normal and cirrhotic liver. M. Rojkind.
3 9 9
Light and electron microscopic innnmolocalization of fibronectin and type I collagen in adult rat hepatocytes during primary culture. B. Clement, M . Rissel, S. Peyrol, J.A. Grimaud, A. Guillouzo.
411
Sinusoids and the Disse space in patients with liver diseases. P. Biouliac-Sage, C. Balabaud, J. Dubroca, L. Boussarie, J.A. Grimaud, Ph. Latry, H . Lamouliatte, A. Quinton.
417
Origin of collagens and fibronectin in normal and fibrotic liver. B. Clement, S. Peyrol, J.P. Campion, Y. Deugnier, J.A. Grimaud, A. Guillouzo.
433
Measurement of serun procollagen type III N-teiminal propeptide in patients with alcoolic liver disease. D.J. Hartmann, J.C. Trinchet, B. Galet, P. Callard, B. Nusgens; Ch.M. Lapiere, M. Beaugrand, G. Ville.
^43
The schistosome egg granuloma as a model of cell-mediated inflammation synthesis and degradation of connective tissue matrix. D.L. Boros.
4 4 9
Fibrous resorption in schistosomal granuloma. Z.A. Andrade, J.A. Grimaud.
461
Antibody to collagen CB-peptides alpha 2-CB(3,5) : a marker of type I collagen breakdown. H. Bnonard, S. Peyrol, S. Guerret-Stocker, M. Druguet, J.A. Grimaud.
473
The effect of malotilate in an experimental model of hepatic fibrosis induced by heterologous serun in the rat. J.M. Dunont, M.F. Maignan, D. Perrissoud. Development of fibrosis in hepatic alveolar echinococcosis : a sequential study in mice infected with Echinococcus multilocularis. D.A. Vuitton, Van-Pierre Tran, S. Guerret-Stocker, J.A. Grimaud, M. Liance, R. Houin.
XIV I n t r a a l v e o l a r f i b r o s i s : a r e v e r s i b l e fotm of pulmonary f i b r o s i s . S. Peyrol, J . F . C o r d i e r , J . A . Grimaud.' D i s t i n g u i s h i n g p a t t e r n s of a l v e o l i t i s and f i b r o s i s in disease. J . F . C o r d i e r , S. Peyrol, C. Takiya, J.A. Grimaud, J . Brune.
hunan
501 lung
P a n c r e a t i c connective m a t r i x changes in chronic p a n c r e a t i t i s . R. Kennedy, L. Uscanga, R. Choux, H. S a r l e s , D.E. Bockman, J . A . Grimaud.
SECTION
507
^21
VI
IMMUNOMODULAT
ION
Monoclonal a n t i b o d i e s t a r g e t i n g f o r cancer inmunotherapy. M.J. Ehibleton, R.W. Baldwin.
529
Inmunosuppressive p r o p e r t i e s of muramyl p e p t i d e s . C. L e d e r e , L. Chedid. The m u l t i p l e a cJt .i vWijdenes. i t i e s of i n t e r f e r o n garmia. J . Banchereau, Purine metabolism and inmunomodulation of monocyte f u n c t i o n s . M. P e t r i n i , P. Goldsclmit-Clermont, F. Ambrogi. I s o p r i n o s i n e ( i n o s i p l e x ) : an inmunological and c l i n i c a l review. J . Wybran.
543
551 571 579
Imuthiol. G. Renoux.
591
Inmunomodulation of macrophage f u n c t i o n s by a t r i - p e p t i d e CIKP) derived frcm IgG. C. A u r i a u l t , M. Joseph, El Hassan Hinmi, A. Capron, A. T a r t a r e .
599
Phospholipids and membrane phenomena involved in the r e l e a s e of mediators of anaphylaxis. Modulation by S-Adenosyl-L-Hcmocysteine and i t s s t r u c t u r e analogs. Y. Pacheco, N. B i o t , M. P e r r i n F a y o l l e , P. Fonlupt, A.F. P r i g e n t , H. Pacheco.
607
E f f e c t of the imnuncmodulator RU 41740 on the p r o l i f e r a t i o n of c u l t u r e d mouse embryo f i b r o b l a s t s . S. Durant, F. Homo-del arche, D. Duval, P. Stnets.
621
Evaluation of the thymus r o l e in the LH g e n e t i c hypertension by thymostimulin CTP-1). J.C.A. F r e i c h e , A. B a t a i l l a r d , J . L . Touraine, M. Vincent, J . Sassard.
625
XV TWo i n - v i t r o e f f e c t s of 40 639 RP in immunity mediated c e l l s . B. Dauvergne, F. Touraine, C. Quincy, J . L . Touraine, F. Floch.
631
Various imnunomodulating e f f e c t s of L-methionine i n - v i t r o . B. Dauvergne, F. Touraine, A. Galy, A. Guichard, J . L . Touraine, S. Ferrant.
635
SECTION
VII
LECTINS
AND
BIOLOGICAL
Identification of lectin like irrmunoa f f i n o e l e c t rophor es i s . R.M.F. Guinet, V. Rogemond, H. P e r r o l l e t . Lectin-induced egg j e l l y .
agglutination
of
A C T I V I T I E S bacterial
adhesins
by 641
microorganisms
in urodelan amphibian
A. Chesnel, H. Lerivray, P. Jego.
647
F i bCaron, r o n e c t i nR. asJ o au bmodel M. e r t . of m u l t i f u n c t i o n a l Modulation of phenobarbital. D. Monnet, J . Fournet.
glycosylation Feger,
D.
of
Biou,
lectin
rat
alpha
G.
Durand,
653 1-acid
glycoprotein
by
P. Cardon, Y. Leroy, B.
Study of the s p e c i f i c i t y of a r a t b r a i n e x t r a c t l e c t i n . R. J o u b e r t , M. Caron, M.A. Deugnier, J . C . Bisconte. V a r i a t i o n s in the p r o p o r t i o n s of microheterogeneous alpha 1 - a c i d g l y c o p r o t e i n in a l c o h o l i c c i r r h o s i s . N. S e t a , G. Durand, J . Agneray, J . Feger, M. Corbie.
661 667
forms of human 673
Assay of PHA m i t o g e n i c i t y on hunan lynphocytes a f t e r e l e c t r o - b l o t t i n g . B. Beal, P. Laurent, A. Gaspar.
679
AUTHOR
683
SUBJECT
INDEX INDEX
687
INTRODUCTORY
LECTURE
PROGRESS IN PLASMA PROTEINS RELATED TO INFLAMMATION
Frank W. Putnam Department of B i o l o g y , Indiana U n i v e r s i t y Bloomington, IN 47405, USA Introduction I t i s a p l e a s u r e and an honor for me to g i v e the i n t r o d u c t o r y Third Symposium. years.
l e c t u r e to the
We can r e f l e c t with pride on the advances of the past
four
I n d e e d , i n the two y e a r s s i n c e the Second Symposium on I n f l a m m a t i o n
Markers, a t r u l y major development has occurred i n knowledge of the m o l e c u l a r b i o l o g y o f a c u t e phase p r o t e i n s and o f the p o l y p e p t i d e l y m p h o k i n e s s u c h as interleukins
which
are
associated
with
i n c r e a s e i n k n o w l e d g e about i n t e r l e u k i n s
inflammation.
I n some ways
the
i s more s t a r t l i n g and s i g n i f i c a n t
than the advances made with acute phase p r o t e i n s ; for the l a t t e r act mainly as markers
of
mediators.
inflammation,
whereas the i n t e r l e u k i n s
As a protein chemist,
the many-named,
are o f t e n the
actual
i t g i v e s me great s a t i s f a c t i o n to see that
and often o v e r l a p p i n g f a c t o r s of immunology and inflammation
are b e i n g p u r i f i e d and shown to be p o l y p e p t i d e s o f d e f i n e d s t r u c t u r e , the genes for which are being cloned and sequenced. biochemical
p r o p e r t i e s , t h e i r chemical
and t h e i r r o l e s
And e q u a l l y important,
their
r e l e v a n c e to the acute phase response,
in inflammation are being c l a r i f i e d ,
as we s h a l l
hear today.
This g i v e s us hope, not o n l y for understanding the b a s i c biochemical
processes
but a l s o f o r i n t e r v e n t i o n to p r e v e n t or reduce i n f l a m m a t i o n by
rational
a p p r o a c h e s o f immunopharmacology. T h i r d Symposium.
These r e p r e s e n t the main themes o f o u r
However, r a t h e r than i n t r o d u c e the c h i e f t o p i c s o f our
Symposium and then t o t r y to a n t i c i p a t e t h e i r h i g h l i g h t s , I h a v e c h o s e n t o r e v i e w r e c e n t p r o g r e s s i n a more l i m i t e d a r e a , n a m e l y , the p l a s m a p r o t e i n s r e l a t e d t o i n f l a m m a t i o n w i t h e m p h a s i s on r e c e n t work o f my own l a b o r a t o r y . This review i s based on the r e c e n t l y p u b l i s h e d Volume IV of my t r e a t i s e , The Plasma P r o t e i n s , which s h o u l d be c o n s u l t e d for references to the work of many laboratories
that
I c i t e (1).
I n the p a s t
few y e a r s
there
has been g r e a t
progress
in e l u c i d a t i n g
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
the
4 structure of plasma proteins, e s p e c i a l l y those of man.
The role of antibodies
in inflammatory processes is being made more clear both by the advances in the structural
study of immunoglobulins
antibodies.
Sequence determination
and by the widespread of the 5 classes
use of
monoclonal
of both human and mouse
immunoglobulins is now complete, but the v o l u m e of sequence data continues to rise exponentially. of m o n o c l o n a l
The same logarithmic law governs the rise in applications
antibodies
in
research,
for d i a g n o s t i c
applications,
and
p o t e n t i a l l y for therapeutic uses.
Sequence
analysis
of
plasma
proteins
entering a similar exponential of sophisticated
other than
phase (Fig. 1).
new methods of
immunoglobulins
First this came about
rapid automatic
sequencing
is
now
because
of proteins.
Now
these methods are hard pressed to keep up with the results of gene cloning and nucleotide
sequencing
techniques which began about
1980.
The consequence
is
that we now know the primary structure for at least 50 of the 100 or so human p l a s m a proteins,
and the carbohydrate
structure
for 25.
The genes for about
40 p l a s m a p r o t e i n s h a v e b e e n c l o n e d , and the c D N A s e q u e n c e and t h e g e n o m i c structure reported in many cases.
Furthermore, we are learning the chromosomal
location of the genes for many human plasma proteins. for the plasma protein, on the s a m e c h r o m o s o m e , transferrin, are a l l
the
and m a y be u n d e r a c o m m o n c o n t r o l .
transferrin
receptor,
and the
l o c a t e d on h u m a n c h r o m o s o m e 3.
the grand design
In some cases, the gene
its receptor, and a related growth factor are
governing
related
For
located example,
p97 m e l a n o m a
antigen
T h i s b e g i n s to g i v e us i n s i g h t
the system that promotes tissue growth and
on the one hand, and inflammation and necrosis on the other.
Another
is the coordinate regulation of expression of serum albumin and t h e g e n e s f o r w h i c h are l o c a t e d o n l y
into
repair example
a
fetoprotein
13.5 kB a p a r t on the s a m e
chromosome.
The lipoproteins represent another example.
Amino Acid Sequence of Human Acute Phase
Proteins
W e n o w k n o w t h e c o m p l e t e a m i n o acid s e q u e n c e of a l m o s t al 1 t h e m a j o r a c u t e phase proteins of man and a l s o the sequence of several proteins of the rat and the mouse. a m i n o acid s e q u e n c e of h u m a n
of the acute phase (AP)
As I reported at the Second Symposium,
a^-acid glycoprotein («^S),
( a j - A T ) , C - r e a c t i v e p r o t e i n (CRP), h a p t o g l o b i n
«j-antitrypsin
(Hp), and f i b r i n o g e n
had already been determined by methods of protein sequencing.
the
(F11)
At that time, I
5
Fig. 1. Increase in amino acid sequence data (excluding immunoglobulins) for all plasma proteins of all species. Updated from Fig. 4, p. 22 of Putnam (1). The dates for publication of the sequence of human plasma proteins are indicated by standard symbols for the proteins. For acute phase reactants the symbols are defined in the text. The Greek letters at the abscissa identify the dates when the complete amino acid (protein) sequences were published for the human light (K , x) and heavy (Y » P . E, O J , A 2» 9 5 % p u r e h u m a n SAP w i t h a y i e l d of 65%. contaminants
Sepharose
in the
covalent polymers. physico-
inflammatory
sera
92
669 K»440 K ^ 232 K»140 K ^
1
2
3
4
5
6
Fig. 1 - Immunoelectrophoresis of human control plasma (lanes 1 and 4), of fractions pooled and concentrated from Sepharose 4B (lane 2) and Sepharose 2B (lane 3). T, antiserum to total human serum, SAP, specific antiserum to SAP protein. Anode at the right.
1 -
2 SAP 3 4
..
^
S * ® ^ "
Fig. 2 - Polyacrylamide gradient gel electrophoresis of purified fractions of SAP. Lanes 1 and 2: low and high M.W. markers. Lanes 3 and 4: fractions pooled and concentrated from Sepharose 4B, lanes 5 and 6 from Sepharose 2B. Anode at the bottom. The gel was stained with 0.5% Coomassie Blue R250 in ethanol:watertacetic acid (9:9:2 v/v).
93
— 4 5
PL
Fig. 3A - SDS p o l y a c r y l a m i d e gel e l e c t r o p h o r e s i s of SAP p u r i f i e d fraction. Lane 1: reduced sample. Lane 2: non reduced sample. Lane 3: non reduced and non heated sample. L a n e s 4 and 5: high and low M . W . m a r k e r s . Stained with C o o m a s s i e Blue. A n o d e at the bottom. B
- T r a n s b l o t on n i t r o c e l l u l o s e m e m b r a n e following S D S - P A G E . The p r i m a r y a n t i s e r u m used was d i r e c t e d to human SAP. L a n e s 1 to 3 as in 3-A.
was explored. M.W.
No d i f f e r e n c e could be o b s e r v e d
in their
In c o n t r a s t , studies p e r f o r m e d on a n a l y t i c a l
respective
IEF g e l s
showed
a h e t e r o g e n e o u s p a t t e r n w h i c h c o n s i s t e d of about 10 to 12 b a n d s (Fig. 4A). according
In a d d i t i o n , a c l e a r l y d i f f e r e n t p a t t e r n was to the o r i g i n of the serum,
c a t h o d a l w h e n isolated from i n f l a m m a t o r y by the i m m u n o b l o t of an a n a l y t i c a l
IEF
serum. This was
(Fig. 4B).
The
p o i n t s of the p r o t e i n were found to be close to those reported normal
(2,12)
i.e., between 5.0 and 6.2 w h e n
serum and b e t w e e n pH 5.5 and 6.7 w h e n
m a t o r y serum.
evident
i.e., SAP b a n d s were
confirmed
isoelectric already
isolated
isolated
more
from
from
inflam-
This d i f f e r e n c e , w h i c h seems to affect equally
w h o l e p a t t e r n , could be related to a change
in the
the
glycosylation
94
A
Fig.
B
4A - A n a l y t i c a l IEF on p u r i f i e d SAP f r a c t i o n s . Lanes 1, 2 and 12: SAP isolated from i n f l a m m a t o r y h u m a n serum. L a n e s 3 to 9: SAP isolated from normal human serum using S e p h a r o s e 4B. Lanes 10 and 11: SAP isolated from n o r m a l h u m a n serum using S e p h a r o s e 2B. T h i c k n e s s of the g e l : 0.2 m m ; a c r y l a m i d e and bis a c r y l a m i d e : T5C2.5LKB a m p h o l i n e s 3.5-10 6% - u r e a : 8M. The gel was run for 3 h o u r s at 3W c o n - s t a n t p o w e r , then silver stained (35). A n o d e at the top. B
- T r a n s b l o t on n i t r o c e l l u l o s e m e m b r a n e after an analytical IEF: same c o n d i t i o n s as above e x c e p t for the LKB ampholines: 3.5-10 (3%), 4-6 (1.7%) and 5-8 (1.7%). L a n e s 1 and 2: SAP isolated from i n f l a m - m a t o r y human serum. Lanes 3 to 6: SAP isolated from normal human serum.
of the p r o t e i n during
the p r o c e s s of i n f l a m m a t i o n .
r e s u l t s have been reported for a l p h a ^ - a n t i t r y p s i n protein
(30-31).
already
reported
Since some m i c r o h e t e r o g e n e i t y (7,29)
in c o n t r a s t
to CRP,
for SAP has
to further e x p l o r e
analytical
IEF involves amino acids s u b s t i t u t i o n s
significance
alpha^-glycobeen
it could be of
importance
if the h e t e r o g e n e i t y
in the g l y c o s y l a t i o n of the protein.
Similar and
In a d d i t i o n ,
observed and/or
in
changes
it will be of
to d e v e l o p t e c h n i q u e s w h i c h will allow d i r e c t
study
95 of SAP in plasma samples, despite its low concentration.
The
progress of immunoblot following IEF, especially using Zeta bind membranes
(32, and Miribel and Arnaud, in preparation)
with more refined and specific staining techniques cate that this will be feasible soon.
together
(33-34)
indi-
Then, the effects of the
inflammation process on the molecule will be possible to study with respect to time and type of triggering mechanism, as already performed for classical acute-phase reactants
(30,31).
Finally,
our result, which do not exclude the existence of a polymorphism in the primary structure of SAP as well as the suggested
associ-
ation of some forms of SAP with the development of amyloidosis (29), raises the question of the significance of SAP during the process of
inflammation.
Acknowledgement Publication No. 734 from the Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina.
Supported in part by grants from the French Foreign
Office, from the Philippe Foundation, Inc., and from Labcatal Laboratories, Montrouge, France.
L. Miribel was a postdoctoral
fellow of the College of Graduate Studies and University
Research,
Medical University of South Carolina.
References 1.
Painter, R.H., I. De Escallon, A. Massey, L. Pinteric, and S.B. Stern. 1982. Ann. N.Y. Acad. Sci. 389, 199-215.
2.
Putnam, F.W. 1984. In: The Plasma Proteins, Vol. 4 (F.W. Putnam, ed.). Academic Press, New York, pp. 5; 24; 29; 49; 61; 111; 179-182; 391.
3.
Haupt H., N. Heimburger, T. Kranz, and S. Baudner. Hoppe-Seyler's Z. Physiol. Chem. 353, 1841-1849.
4.
Pepys, M.B., A.C. Dash, E.A. Munn, A. Feinstein, M. Skinner, A.S. Cohen, H. Gewürz, A.P. Osmand, and R.H. Painter. 1977. Lancet, 1029-1031.
5.
De Beer, F.C., and M.B. Pepys. 17-31.
1982.
1972.
J. Immunol. Meth. 50,
96 6.
S k i n n e r , M . , A.S. C o h e n , T. S h i r a m a , and S. C a t h c a r t . J. Lab. Clin. Med. (4), 604-614.
7.
A n d e r s o n , J.K. and J.E. M o l e . 1982. In: C. R e a c t i v e P r o t e i n and T h e P l a s m a R e s p o n s e to Tissue Injury (I. K u s h n e r , J.E. V o l a n a k i s , and H. G e w ü r z , eds.). Ann. N.Y. Acad. Sei. 389, 216-234.
8.
T h o m p s o n , A.R. and D . L . Enfield. 4304-4311.
9.
B i n e t t e , P., M. B i n e t t e , and E. C a l k i n s . 143, 2 5 3 - 2 5 4 .
1978. B i o c h e m i s t r y 1974.
1978.
17(20),
Biochem.
10. P i n t e r i c , L., S.N. A s s i m e h , D.J.C. K e l l s , and R.H. 1976. J. Immunol. 117, 79-81. 11. B e n s o n , M . D . and M . Skinner. 78-83.
1974.
J.
Painter.
J. Lab. C l i n . M e d .
92,
12. B a l t z , M . L . , F.C. De B e e r , A. F e i n s t e i n , E.A. M u n n , C.P. M i l s t e i n , T.C. F l e t c h e r , J.F. M a r c h , J. T a y l o r , C. B r u t o n , J.R. C l a m p , A . J . S . D a v i e s , and M . B . Pepys. 1982. In: C. R e a c t i v e P r o t e i n and the P l a s m a R e s p o n s e to T i s s u e Injury (I. K u s h n e r , J.E. V o l a n a k i s , and H. G e w ü r z , eds.). Ann. N.Y. A c a d . Sei. 389, 49-75. 13. O s m a n d , A . P . , B. F r i e d e n s o n , H. G e w ü r z , R.H. P a i n t e r , T. H o f m a n n , and E. S h e l t o n . 1977. Proc. N a t l . Acad. Sei. U . S . A . Ti, 7 3 9 - 7 4 3 . 14. S k i n n e r , M . , M.B. Pepys, A.S. C o h e n , L.M. H e l l e r , and J.B. Lian. 1980. In: A m y l o i d and A m y l o i d o s i s (G.G. G l e n n e r , P. Pinho e C o s t a , and F. De F r e i t a s , eds.). Excerpta Medica, A m s t e r d a m , E l s e v i e r , New Y o r k , pp. 384-391. 15. O l i v e i r a , E . B . , E.C. G o t s c h l i c h , and T . Y . Liu. N a t l . A c a d . Sei. U.S.A. 1_4, 3 1 4 8 - 3 1 5 1 .
1977.
Proc.
16. O l i v e i r a , E.B., E.C. G o t s c h l i c h , and T . Y . Liu. B i o l . Chem. 254, 489-502.
1979.
J.
17. S k i n n e r , M. , J.L. V a i t u k a i t i s , A.S. C o h e n , and M . D . 1979. J. Lab. Clin. Med. 9_4, 633-638.
Benson.
18. P e p y s , M . B . , M . L . B a l t z , K. G o m e r , A . J . S . D a v i e s , and M. Doenhoff. 1979. N a t u r e (London) 2JB, 259-261. 19. P e p y s , M . B . , A.C. D a s h , R.E. M a r k h a m , H.C. T h o m a s , B.D. W i l l i a m s , and A. Petrie. 1978. C l i n . Exp. Immunol. 32, 119-124. 20. P e p y s , M . B . , M.L. B a l t z , R.F. Dyck, F.C. De B e e r , D.J. Evans, A . F e i n s t e i n , C.P. M i l s t e i n , E.A. M u n n , N. R i c h a r d s o n , J. M a r c h , T.C. F l e t c h e r , A.J.B. D a v i e s , K. G o m e r , A.S. C o h e n , M. S k i n n e r , and G . G . B . Klaus. 1980. In: A m y l o i d and A m y l o i d o s i s (G.G. G l e n n e r , P. Pinho e C o s t a , and F. De F r e i t a s , eds.). E x c e r p t a M e d i c a , A m s t e r d a m , E l s e v i e r , N e w York pp. 373-383.
97 21. L a u r e l l , C.B. 22. S v e n d s e n , P.J.
1966. 1973.
A n a l . Biochem. _15, 45-52. Scand. J. Immunol. Suppl.
23. G r a b a r , P. and C.A. W i l l i a m s . 10, 193-194.
1953.
69-70.
Biochim. Biophys.
Acta
24. P h a r m a c i a Fine C h e m i c a l s 1980. In: P o l y a c r y l a m i d e Gel Electrophoresis. L a b o r a t o r y T e c h n i q u e s , pp. 58-61. 25. L a e m m l i , U.K. 1970.
Nature
227,
680-685.
26. A r n a u d , P., C. C h a p u i s - C e l l i e r , P. V i t t o z , and H.H. 1978. J. Lab. Clin. M e d . 92, 177-186. 27. T o w b i n , H., T. S t a e h l i n , and J. G o r d o n . Acad. Sci. U.S.A. 16, 4350-4354.
1979.
Fudenberg.
Proc.
Natl.
28. L a u r e n t , P. 1983. In: Etude B i o c h i m i q u e de la P r o t e i n e C R e a c t i v e H u m a i n e (CRP), T h e s i s , U n i v e r s i t e Claude B e r n a r d , L y o n , F r a n c e , pp. 28-40. 29. Pepys, M . C . and M . L . Baltz.
1983.
Adv.
Immunol.
30. V a u g h n a n , L., M.A. Lorier, and R.W. C a r r e l . B i o p h y s . Acta 701, 339-345.
1982.
31. H a n s e n , J . E . S . , V.A. Larsen, and T.C. B o g - H a n s e n . C l i n . Chim. Acta 138, 41-47. 32. G e r s h o n i , J.M. and G.E. Palade. 1982. 396-405.
1984.
141-212.
Biochim. 1984.
Anal. B i o c h e m .
33. L a n z i l l o , J . J . , J. S t e v e n s , J. Tumas, and B.L. 1983. E l e c t r o p h o r e s i s 4 (4), 313-315. 34. V i s s i n g , H. and O . D . N a d s e n .
3J,
124,
Fanburg.
Electrophoresis
5,(5),
35. M e r r i l , C . R . , D. G o l d m a n , S.A. S e d m a n , and M . H . Ebert. S c i e n c e 211, 1 4 3 7 - 1 4 3 8 .
313.
1981.
SERUM AMYLOID EVALUATION
P COMPONENT
(SAP)
AND
HEMOSTASIS:
A
CONTINUING
B . A . Fiedel D e p a r t m e n t of I m m u n o l o g y / M i e r o b i o l o g y , R u s h M e d i c a l C e n t e r , C h i c a g o , I l l i n o i s , 6 0 6 1 2 , USA ( P r e s e n t A d d r e s s : D i v i s i o n of I m m u n o l o g y , J a m e s N . G a m b l e I n s t i t u t e of M e d i c a l R e s e a r c h , C i n c i n n a t i , O h i o , 1)5219, U S A )
C . S . L . Ku D e p a r t m e n t of B i o c h e m i s t r y , M o l e c u l a r a n d C e l l B i o l o g y , Northwestern University, Evanston, Illinois, 60201, USA.
Introduction
R e c e n t l y , we (1) a n d o t h e r s (2) i n v e s t i g a t e d a r o l e f o r S A P in coagulative processes. In p a r t i c u l a r , we f o u n d t h a t S A P c o u l d i n t e r f e r e w i t h t h e c o n v e r s i o n of f i b r i n o g e n to f i b r i n , a n a c t i v i t y e n h a n c e d by t h e p r e s e n c e o f h e p a r i n , a n d c o u l d a l t e r f i b r i n - f i b r i n polymerization. T h e p u r p o s e of t h i s p r e s e n t a t i o n is to e l a b o r a t e u p o n d a t a o b t a i n e d f r o m our c o n t i n u i n g e v a l u a t i o n of the e f f e c t s of S A P u p o n h e m o s t a t i c e v e n t s . T h e q u e s t i o n s we a s k e d i n c l u d e d : is t h e a n t i c o a g u l a n t a c t i v i t y e x p r e s s e d b y S A P r e l a t e d t o c h a n g e s in a n t i - t h r o m b i n I I I b e h a v i o r , d o e s S A P i n c o r p o r a t e i n t o f o r m i n g c l o t s , d o e s it a f f e c t n o r m a l c l o t r e t r a c t i o n , a n d d o e s it h a v e a n effect upon Factor XIII activity?
Materials
and
Methods
S e r u m a m y l o i d P c o m p o n e n t was i s o l a t e d as d e s c r i b e d (1,3). APTT , PT a n d t h r o m b i n c l o t t i m e s w e r e a l s o p e r f o r m e d a s d e s c r i b e d ( 1 ) , as w e r e f i b r i n o p e p t i d e A a n d f i b r i n p o l y m e r i z a t i o n a s s a y s . Antit h r o m b i n I I I a c t i v i t y w a s d e t e r m i n e d u s i n g a k i t p r o v i d e d by Abbott Laboratories and used chromogenic substrate methodology; c l o t r e t r a c t i o n w a s a s s e s s e d a c c o r d i n g to ( 1 , 1 ) .
Results
and
Discussion
W e h a v e s h o w n t h a t S A P a n d h e p a r i n o p e r a t e d s y n e r g i s t i c a 1 1 y to i n c r e a s e c l o t t i m e s in c i t r a t e d c e l l - f r e e p l a s m a ( C F P ) w h e n C F P c o a g u l a t i o n w a s i n i t i a t e d t h r o u g h t h e i n t r i n s i c , e x t r i n s i c or terminal pathways; data illustrating these points are p r e s e n t e d Tables I-III.
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
in
100 TABLE APTT
CLOT
TIMES
SAP
IN T H E
HEP
I
PRESENCE
+/-
OF
SAP
Clot
Ug/ml
AND
HEPARIN
Time
Average
(Seconds) of
_
_
42 . 0
-
+
60.6
+ + + +
62.9 60 . 2
10 25 40 60 80
110.8 138.0 167.6 >>200 (no
+ +
1 00
TABLE TISSUE
HEP
+ /-
PRESENCE
Clot Times (Seconds) Average of T h r e e
Ug/ml -
34.2 -
-
53.9
+ + +
10 20 40 60
62.3 80.7 153.2 187.4
+ +
100
>>200
TABLE THROMBIN
SAP Ug/ml
c lot)
11
T H R O M B O P L A S T I N T I M E IN T H E OF SAP AND HEPARIN
SAP
Three
TIMES
IN
HEP
THE
+/-
_ -
+
20
+
25
+
(no
clot)
III
PRESENCE
OF
SAP
Clot
AND
HEPARIN
Time
32.6; 51.2; 57.4; >>200
(Seconds)
33.1 53.4 62.1
(no
clot)
H o w S A P and h e p a r i n s y n e r g i z e d to b r i n g a b o u t i n c r e a s e d c l o t t i n g t i m e s w a s f i r s t a p p r o a c h e d by a s k i n g w h e t h e r SAP a n d / o r h e p a r i n could alter r e g u l a t o r y p a t h w a y s and/or d e - s t a b i l i z e systems c r i t i c a l to the f o r m a t i o n of a p a t e n t c l o t . As p r e s e n t e d in T a b l e I V , it b e c a m e e v i d e n t t h a t SAP and h e p a r i n r e d u c e d the g e n e r a t i o n of f i b r i n o p e p t i d e A (F PA ) from f i b r i n o g e n .
101 TABLE
IV
E F F E C T O F SAP A N D H E P A R I N ON T H R O M B I N C L O T T I M E , R E L E A S E O F FI B R I N O P E P T I D E A AND T H R O M B I N A C T I V I T Y Plasma
Clot
Control + SAP (50 y g / m l ) + Heparin (0.08 U / m l ) + SAP (50 y g / m l ) Heparin (0.08 U / m l )
Times
(s)
Released F PA ( y g / m l )
Thrombin Activity (U/ml)
23 ..9 26 ,.8
1 5 1 6
(100?) (106%)
0 .22 . 0 .27 ,
48 ,. 2
9
( 6 0?)
0. , 1 7
200 ,. 0
5
(
0.. 25
32?)
T h a t SAP a n d h e p a r i n r e d u c e d FPA l e v e l s w a s an i m p o r t a n t f i n d i n g s i n c e r e d u c e d FPA l e v e l s t r a n s l a t e into l e s s a v a i l a b l e f i b r i n for cross-linking, hence a less patent clot. S A P and h e p a r i n a l s o interfered with fibrin monomer p o l y m e r i z a t i o n ; thus, these stages of c o a g u l a t i o n a p p e a r e d to be t h o s e p r e d o m i n a t e l y a f f e c t e d . W h e t h e r S A P m o d i f i e d the r e g u l a t o r y i n f l u e n c e of a n t i - t h r o m b i n III ( A T - I I I ) on t h r o m b i n a c t i v i t y r e s u l t i n g in r e d u c e d FPA p r o d u c t i o n was tested next. As d e p i c t e d in T a b l e V, SAP at c o n c e n t r a t i o n s w h i c h i n c r e a s e d c l o t t i m e s in CFP (20-1 0 0 y g / m l ; T a b l e s I - I I I ) r e d u c e d s l i g h t l y , r a t h e r t h a n e n h a n c e d , A T - I I I a c t i v i t y as w o u l d h a v e b e e n p r e d i c t e d f r o m the FPA d a t a . T h u s , SAP a p p e a r e d to b e a n t i - h e p a r i n in the A T - I I I a s s a y .
TABLE EFFECTS SAP
(yg/ml) 0 50 100 150 250
V
O F S A P ON A N T I T H R O M B I N IN N O R M A L P L A S M A
III
? Antithrombin
ACTIVITY III
Activity
92.5 98.0 86.0 8 4.0 85.5
F i b r o n e c t i n a n d f i b r i n ( - o g e n ) are k n o w n to be i n c o r p o r a t e d into f o r m i n g c l o t s a n d c r o s s - l i n k e d t h r o u g h the a c t i o n of c o a g u l a t i o n Factor XIII. As a p p r o p r i a t e l y a g g r e g a t e d S A P h a s b e e n r e p o r t e d to b i n d w i t h f i b r o n e c t i n (5), a n d n e p h e l o m e t r i c a n a l y s e s s u g g e s t an i n t e r a c t i o n b e t w e e n SAP and f i b r i n o g e n (1), we q u e s t i o n e d w h e t h e r S A P c o u l d d e p o s i t in a f o r m i n g c l o t and i n t e r f e r e w i t h c l o t retraction. As p r e s e n t e d in T a b l e V I , S A P a l o n e i n c o r p o r a t e d i n t o f o r m i n g c l o t s , a n d t h i s w a s p o t e n t i a t e d by h e p a r i n . Furthermore, S A P and h e p a r i n s y n e r g i s t i c a 1ly r e d u c e d c l o t r e t r a c t i o n by - 1 9 ? o v e r the c o n t r o l ( T a b l e V I I ) . S A P a l o n e at s u p r a - p h y s i o 1 o g i c a l c o n c e n t r a t i o n (200 y g / m l ) was i t s e l f an i n h i b i t o r of c l o t retraction.
102 TABLE
VI
I N C O R P O R A T I O N OF 1 2 5 I - S A P C L O T S IN T H R O M B I N - T R E A T E D
SAP
(ug/ml)
%
INTO FIBRIN FIBRINOGEN*
Incorporation
Control
0
+ SAP (30 y g / m l ) Heparin
17 .9
+ SAP (50 y g / m l )
45 .1
+ SAP (50 y g / m l ) Heparin
61.5
*The concentration was 1 U/ml.
of
TABLE
heparin
used
VII
E F F E C T OF S A P , H E P A R I N AND S A P / H E P A R I N C L O T R E T R A C T I O N OF N O R M A L P L A S M A
Platelet
Rich
Plasma
Control + SAP (80 p g / m l ) + SAP ( 2 0 0 u g / m l ) + H e p a r i n (0.02 U / m l ) + SAP (80 y g / m l ) H e p a r i n (0.02 U / m l )
% Clot Retraction
ON
%
Inhibition
57 50 43 57
0 12.5 25 . 0 0
46
19.0
C r i t i c a l to the d e v e l o p m e n t of c l o t r e t r a c t i l e f o r c e is coagulation Factor XIII (FXIII). W h e n we a s s e s s e d w h e t h e r S A P a n d / o r h e p a r i n c o u l d m o d i f y F X I I I a c t i v i t y ( T a b l e V I I I ) , we o b s e r v e d t h a t e a c h SAP and h e p a r i n i n h i b i t e d p u r i f i e d F X I I I , a s t h e y did in c o m b i n a t i o n ; h o w e v e r , in c o m b i n a t i o n , S A P r e d u c e d s u b s t a n t i a l l y the m o r e n e g a t i v e i n f l u e n c e of h e p a r i n on F X I I I activity. This r e p r e s e n t e d , along with A T - I I I , a second antih e p a r i n e x p r e s s i o n of S A P .
103 TABLE EFFECTS
Factor
XIII
Vili
O F SAP A N D H E P A R I N ON T H E OF PURIFIED FACTOR X H I a I n c o r p o r a t i o n of Monodansyl Group (uMole/hr) Representative Assay
ACTIVITY
% C h a n g e in Activity
Control
1 .98
0
+
1.28
-36
+ SAP (100 p g / m l )
1 .62
-18
+
1.70
- 1 1)
Heparin (0.1 U / m l )
SAP/Heparin
T h e d a t a p r e s e n t e d h e r e i n i l l u s t r a t e t h a t the p r e v i o u s l y a p p r e c i a t e d a n t i c o a g u l a n t p r o p e r t i e s of S A P in the p r e s e n c e of h e p a r i n r e l a t e to a n i n h i b i t i o n in f i b r i n g e n e r a t i o n f r o m fibrinogen and decreased f i b r i n - f i b r i n p o l y m e r i z a t i o n . This a f f e c t c a n be e x t e n d e d f u r t h e r to c l o t r e t r a c t i o n , p e r h a p s as a c o n s e q u e n c e of SAP d e p o s i t i n g ( b i n d i n g ) in f o r m i n g c l o t s , b u t n o t to the m o d i f i c a t i o n by SAP of A T - I I I or F X I I I a c t i v i t y w h e r e its e x p r e s s e d n a t u r e is a n t i - h e p a r i n .
Ac k n o w l e d g e m e n t F u n d e d , in p a r t , by a g r a n t ( H L - 2 3 1 5 7 ) f r o m the N I H . B A F is r e c i p i e n t of R e s e a r c h C a r e e r D e v e l o p m e n t A w a r d H L - 0 0 6 1 4 f r o m the NIH. C S L K p e r f o r m e d a s p e c t s of t h i s w o r k as p a r t i a l f u l f i l l m e n t of the r e q u i r e m e n t s for the P h . D . D e g r e e in the D e p a r t m e n t of Immunology/Microbiology, Rush Medical Center, Chicago, USA.
References 1.
K u , C . S . L . and B . A. F i e d e l . 1 9 8 3 . M o d u l a t i o n of f i b r i n f o r m a t i o n by h u m a n s e r u m a m y l o i d P c o m p o n e n t (SAP) a n d h e p a r i n . J. E x p . M e d . 1 5 8 : 7 6 7 - 7 8 0 .
clot
2.
P e p y s , M . B . , G . J . B e c k e r , R . F . D y c k , A. M c C r a w , P. H i l g a r d , R . E . M e r t o n a n d D . P . T h o m a s . 1 9 8 0 . S t u d i e s of h u m a n s e r u m a m y l o i d P - c o m p o n e n t (SAP) in r e l a t i o n to c o a g u l a t i o n . C l i n i c a Chimica Acta 1 05:83-91 .
104 3.
F i e d e l , B . A . , C . S . L . K u , J . M . I z z i a n d H. G e w u r z . 1 9 8 3 . S e l e c t i v e i n h i b i t i o n of p l a t e l e t a c t i v a t i o n by the a m y l o i d coraponent of s e r u m . J. I m m u n o l . 131 : 1 11 6 - 1 1 1 9 .
i) .
Bowie, E . J . W . 1971. Mayo C l i n i c L a b o r a t o r y M a n u a l Hemostasis. Saunders, Philadelphia. pp29~31•
5.
de B e e r , F . C . , M . L . B a l t z , S. H o l f o r d , A . F e i n s t e i n a n d P e p y s . 1 9 8 1 . F i b r o n e c t i n a n d C M - b i n d i n g p r o t e i n are s e l e c t i v e l y b o u n d by a g g r e g a t e d a m y l o i d P c o m p o n e n t . J . Med. 154:1131-1119.
P-
of M.B. Exp.
MECHANISM OF INDUCTION OF SYNTHESIS OF SERUM AMYLOID P-COMPONENT (SAP) BY MOUSE HEPATOCYTES IN CULTURE
Richard F . Mortensen Department of M i c r o b i o l o g y , Ohio State U n i v e r s i t y Columbus, Ohio 43210, USA
Introduction A systemic inflammatory response i s characterized by the s y n t h e s i s of a group of blood p r o t e i n s c o l l e c t i v e l y termed acute phase reactants (APRs).
Serum
amyloid P-component (SAP) i s the major APR of mice and i s a member of the pentraxin family of p r o t e i n s , which includes C - r e a c t i v e protein (CRP), the prototypical
APR of man ( 1 ) .
Mouse SAP i s a 230 Kd a l p h a - g l y c o p r o t e i n composed
of two i n t e r a c t i n g p e n t r a x i n s , each containing f i v e i d e n t i c a l 28 Kd subunits (2, 3).
SAP has been p u r i f i e d on the b a s i s of i t s Ca + + -dependent binding
s p e c i f i c i t y for the galactan in agarobiose that i s s u b s t i t u t e d with pyruvate at the 4 , 6-enol p o s i t i o n ( 4 ) .
The induction of new APR s y n t h e s i s by the l i v e r
has long been appreciated as an event r e q u i r i n g a blood born mediator(s)
(5).
The i d e n t i f i c a t i o n of one of the mediators as i n t e r l e u k i n 1 ( I L 1) was f i r s t made using the induction of serum amyloid A (SAA) protein s y n t h e s i s by mouse hepatocytes treated with monokines (6) and l a t e r with p a r t i a l l y p u r i f i e d IL 1 (7).
E a r l i e r work by Kampschmidt ( r e v . i n 8) a l s o c l e a r l y implicated leukocyte
endogenous mediator, which l a t e r was found to be i d e n t i c a l or s i m i l a r to IL 1, i n APR s y n t h e s i s in the r a b b i t . We have recently e s t a b l i s h e d in v i t r o c u l t u r e c o n d i t i o n s for the induction and s y n t h e s i s of mouse SAP by hepatocytes ( 9 ) .
C o c u l t u r i n g the hepatocytes with
e i t h e r inflammatory ( e l i c i t e d ) or f u l l y activated macrophages (M4>s) g r e a t l y enhanced SAP production; furthermore, the a d d i t i o n of p u r i f i e d mouse IL 1 a l s o r e s u l t e d in a s u b s t a n t i a l
increase in the s y n t h e s i s of SAP ( 1 0 ) .
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
The mechanism
106 whereby IL 1 and/or ftys increase SAP synthesis may depend on an increase in the rate of SAP synthesis per c e l l , an increase in the number of SAP-secreting hepatocytes (recruitment), or p o s s i b i l y both.
The experiments described herein
were designed to determine the mechanism of the SAP response. Methods and Materials The methodology for c u l t u r i n g isolated mouse hepatocytes under conditions that result in SAP induction and synthesis i s described elsewhere ( 9 ) .
A s i n g l e cell
assay for detecting individual SAP-secreting hepatocytes was developed by using a sandwich ELISA procedure.
The assay i s based on the "capture" of the
SAP-secreted by a s i n g l e hepatocyte by s o l i d phase anti-SAP and then l o c a l i z i n g the enzyme (horseradish peroxidase, HRP) substrate reaction in an agarose s o l u t i o n ( F i g . 1). The reagents used are:
monospecific rabbit anti-mouse SAP (IgG) ( 3 ) , a
b i o t i n y l a t e d IgG antibody of the same s p e c i f i c i t y , avidin-HRP and o-phenylenediamine as the chromogen.
The dark spots observed represent the
" f o o t p r i n t " of a s i n g l e SAP-secreting hepatocyte.
Hepatocytes incubated for 30
hrs at 2.5 x 10 3 cells/cm 2 or 2 x 104 cells/35 mm t i s s u e culture plate gave c l e a r l y separated spots that permitted accurate counting.
Mouse SAP in the
culture f l u i d was quantitated by competitive ELISA as described previously (10). P u r i f i e d mouse IL 1 was obtained by the procedure described by Mizel (11) using supernatants from the superinduced P388Di (adherent) macrophage l i n e (12). s i n g l e preparation of 320 units/ml was used.
A
A macrophage supernatant was also
obtained from a 30 hr culture of t h i o g l y c o l 1 ate e l i c i t e d (3 days) peritoneal exudate adherent c e l l s (85-92% cytoplasmic esterase p o s i t i v e ) from C57BL/10ScN (LPS-unresponsive) mice.
IL 1 and the M(> culture supernatant were
chromatographed on a B i o - S i l TSK-250 (G 3000 SW) HPLC column (Bio-Rad, Richmond, CA).
107
T TT T T T
Ariti SAP A n t i b o d y
^
Hepatocytes SAP
VYVT
T TT
Biotinylated A n t i b o d y
4 * T T Figure 1.
r
Avidin-HPR
1
4
Procedure for detecting a single SAP-producing hepatocyte by a Reverse Enzyme-Linked Immunosorbent Spot (RELISPOT) assay.
RESULTS Macrophage mediated recruitment of hepatocytes.
Previous studies by us showed
that elicited Ms added to isolated hepatocytes resulted in increased SAP production (10); however, we did not know whether the increase in SAP levels reflected an increase in the fraction of SAP-secreting hepatocytes.
Using a
single-cell assay to detect the number of such cells, a 10-fold increase in the number of SAP-secreting hepatocytes was observed in the presence of elicited M$s at a ratio of 8/1 of hepatocytes/M)>s (Fig. 2). not alter the number of SAP-secreting cells.
Resident peritoneal Ms did
Inflammatory peritoneal M$s that
accumulate in response to a stimulus are not fully activated and secrete small amounts of IL 1 (13); however, the addition of these cells to hepatocytes at ratios as low as 1/32 (M$/hepatocyte) generated a significant increase in the number of SAP-secreting hepatocytes (Fig. 2).
The addition of syngeneic
108
x
50
CM
CO Ui I>o
40
0
H < Q. LU 1 O
30
Hi
0
HI CO 1
20
CL
s from C57BL/10SN mice cultured with syngeneic C57BL/10Sc hepatoyctes at 2xl0 4 hepatocytes/2.5xl0 3 M+ s in 35 mm plates.
Table 2.
Recruitment of Hepatocytes into SAP Synthesis by a Mf Culture Supernatant SAP Secreting Hepatocytes
Mi> Culture Supernatant (Dilution)
IL 1 (units/ml)
undi1.
6.0
7
(±D
1/5
3.0
10
(±3)
1/10
1.5
57
(±6)
1/20
0.75
41
(±4)
1/40
0.37
29
(±2)
1/80
0.18
23
(±6)
per 2 x l 0 4 C e l l s (SO)
measured by the standard thymocyte p r o l i f e r a t i o n assay for IL 1 (13). Both the
culture supernatant and IL 1 preparation were separated on the
b a s i s of size by HPLC and the f r a c t i o n s tested for t h e i r a b i l i t y to not only r e c r u i t , but also induce SAP s y n t h e s i s .
Monokines with a Mr of 40 Kd and 79 Kd
were most active in the r e c r u i t i n g assay ( F i g . 3 ) .
The IL 1 preparation
110
displayed much less r e c r u i t i n g a c t i v i t y .
The most active f r a c t i o n in the LAF
assay contained proteins of 16 Kd M r ; however, only the 32 Kd M r proteins displayed s i g n i f i c a n t r e c r u i t i n g a c t i v i t y ( F i g . 3 ) . Table 3.
When SAP l e v e l s in culture
Recruitment of Hepatocytes into SAP Synthesis By P u r i f i e d Mouse IL 1 IL 1
SAP-Secreting Hepatocytes
units/ml
per 2xl0 4 C e l l s (SO)
0
6 (±3)
13.0
18 (±7)
6.5
25 (±6)
3.2
15 (±5)
1.6
8 (±2)
0.8
7 (±2)
Figure 3.
Hepatocyte r e c r u i t i n g a c t i v i t y of a Mt> culture supernatant and
p u r i f i e d IL 1 separated by HPLC gel
filtration.
111
supernatants were measured in response to the same f r a c t i o n s containing monokines, the most s i g n i f i c a n t SAP production was induced by the 16 Kd protein within the IL 1 preparation ( F i g . 4 ) .
The enhanced SAP production by the 35 Kd
and 71 Kd monokines in the W)> culture supernatant most l i k e l y i s a r e f l e c t i o n of increased number of hepatocytes recruited into SAP s y n t h e s i s .
Thus,
p u r i f i e d IL 1 displayed minimal r e c r u i t i n g a c t i v i t y , but could induce an increase in the amount of SAP synthesized per c e l l . 16 Kd
K' Figure 4.
SAP production by hepatocytes in response to proteins present in
a Mtf> culture supernatant or an IL 1 preparation separated by size on HPLC. Effect of Anti-Mouse IL 1.
Since non IL 1 monokines appear to be
responsible for the recruitment of hepatocytes, a well-characterized goat anti-mouse IL 1 was used to test i t s effect on both hepatocyte recruitment
112 and SAP production (14).
In preliminary experiments a d i l u t i o n of 1/5000 was
found to neutralize the LAF a c t i v i t y of the p u r i f i e d IL 1 preparation. Treatment of IL 1 (4 units/ml) and the M)> culture supernatant with a n t i - I L 1 (1/500) resulted in i n h i b i t i o n of SAP production, but did not a l t e r hepatocyte recruitment a c t i v i t y (Table 4 ) .
Table 4.
Additional properties of the r e c r u i t i n g
Effect of Goat Anti-Mouse IL 1 on SAP Production and Hepatocyte Recruitment SAP-Secreting
Addition to Hepatocytes
AntiMo IL 1
SAP ng/ml
IL 1 (4 units/ml)
None(a)
323 (±15)
25 (±3)
1/500
132 (±33)
31 (±7)
235 (±15)
100 (±14)
246 (±24)
101 (±12)
-Culture Supernatant
a
None 1/500
Cells/2xl04
Controls contained a 1/500 d i l u t i o n of preimmune serum.
monokines are s e n s i t i v i t y to heat (70° C, 15 min), i n a c t i v a t i o n by proteinase-K and reduction in a c t i v i t y by exposure to pH 2 and pH 10.
The monokine-driven
r e c r u i t i n g a c t i v i t y was not s e n s i t i v e to either phenylglyoxal treatment which abolishes IL 1-driven LAF a c t i v i t y (13) or anti-a/g interferon antibodies.
The
r e s u l t s suggest that IL 1 alone does not drive APR s y n t h e s i s , but requires the additional monokines that i n i t i a l l y recruit hepatocytes
into subsequent IL
1-dependent induction of new SAP s y n t h e s i s .
Discussion
The increase in the blood concentration of APRs t r a d i t i o n a l l y was thought to reflect increased synthesis and secretion by each l i v e r parenchymal cell.
Since hepatocytes have been found to be heterogenous with respect to
113 serum p r o t e i n synthesis (15), i t
seemed l o g i c a l
that hepatocytes might also be
heterogenous in t h e i r response to the mediator(s) Evidence f o r sequential born mediators was f i r s t (16, 17).
inducing APR s y n t h e s i s .
recruitment of hepatocyte synthesis of an APR by blood shown f o r rabbit CRP by Kushner and his
colleagues
An increase in the number of hepatocytes s e c r e t i n g f i b r i n o g e n
and haptoglobulin
(19) were shown some years ago using
(18)
immunofluorescent
s t a i n i n g methods. The f i n d i n g s reported here show that recruitment can be examined in v i t r o with an a p p r o p r i a t e l y
s e n s i t i v e method for enumerating
single
hepatocytes s e c r e t i n g an APR. A scheme d e p i c t i n g the r o l e of IL 1 and the other monokines in the induction of ARP synthesis i s shown in Figure 5.
Multiple biological
inflammation have been described (reviewed in 20). M4>s need to be a c t i v a t e d to secrete s u b s t a n t i a l
functions
E l i c i t e d or
f o r IL 1 i n
inflammatory
amounts of IL 1 (21);
we have r e c e n t l y reported that p u r i f i e d mouse SAP s e l e c t i v e l y
however,
induces IL 1
INTRACELLULAR PATHOGENS or INFLAMMATORY STIMULUS
l
SAA FIBRINOGEN
Figure 5.
The c e l l u l a r and molecular components that p a r t i c i p a t e
induction of synthesis of an APR.
in the
114 production by inflammatory MJ>s under conditions that excluded endotoxin contamination (22).
Thus SAP at least in the mouse may function as an
amplifier of the acute phase response and i n d i r e c t l y contribute to heightened host resistance.
Further studies of the molecular events leading to the
induction of APR synthesis may provide a basis for modifying the inflammatory response.
Acknowledgement
This work was supported by USPHS grant CA 30015.
I thank Dr. Steven Mizel
for
h i s generous g i f t of goat anti-mouse IL 1.
References
(1)
Pepys, M.B., M.L. B a l t z .
(2)
Osmand, A . P . , B.F. Friedenson, H. Gewurz, R.H. Painter, T. Hoffman, E. Shelton. 1977. Proc. Natl. Acad. S c i . USA 74, 739.
(3)
Le, P . T . , M.T. M u l l e r , R.F. Mortensen.
(4)
Hind, C.R., P.M. C o l l i n s , 0. Renn, R.B. Cook, D. Caspl , M.L. B a l t z , M.B. Pepys. 1984. J . Exp. Med. ^ i , 1058.
(5)
Kushner, I .
(6)
S e l i n g e r , M.J. K.P.W.J. McAdam, M.M. Kaplan, J.D. Sipe, S.N. Vogel, D.L. Rosenstreich. 1980. Nature 285, 498.
(7)
S z t e i n , M.B., S.N. Vogel, J.D. Sipe, J . J . Oppenheim. Immunol. 63^ 164.
(8)
Kampschmidt, R.A.
(9)
Le, P . T . , R.F. Mortensen.
1984.
IN VITRO.
(10)
Le, P . T . , R.F. Mortensen.
1984.
J . Leuk. B i o l .
(11)
M i z e l , S . B . , D. Mizel.
(12)
M i z e l , S . D . , J . J . Oppenheim, D.L. Rosenstreich. 120, 1504.
1982.
1983.
Adv. Immunol.
1982.
Ann. N. Y. Acad. S c i .
1984.
34, 141.
J . Immunol.
129, 665.
389, 39.
1981.
Cell.
J . Leuk. B i o l . 36, 341.
1981.
J . Immunol.
20, 505. 35, 587.
26, 834. 1978.
J . Immunol.
115 (13)
Mizel, S.B.
1982.
Immunol. Rev. 63; 51.
(14)
M i z e l , S . B . , M. Dukovich, J . Rothstein.
(15)
Jungermann, K . , D.Sasse.
1978.
TIBS 3_, 198.
(16)
Kushner, I . , G. Feldman.
1978.
J . Exp. Med. 148, 466.
(17)
Macintyre, S . S . , D. Schultz, I . Kushner. 389, 76.
(18)
Forman, W.8., M . I . Barnhart.
(19)
Peters, J . H . , C.A. Alper.
(20)
D i n n a r e l l o , C.
(21)
Oppenheim, J . J . , B.M. Stadler, R.P. Siraganian, M. Mage, B. Mathieson. 1982. Fed. Proc. 41, 257.
(22)
S a r l o , K.T., R.F. Mortensen.
1984.
1964.
1965.
1983.
1982.
J . Immunol. 131:1834.
Ann. N.Y. Acad. S e i .
J . Am. Med. Assoc.
J. Clin. Invest.
187, 128.
45:314.
Rev. I n f e c t . D i s .
1985.
C e l l . Immunol.
93, 398.
REACTIVITY OF HUMAN SERUM AMYLOID P PROTEIN (SAP) WITH CONCANNAVALIN A
A. Mackiewicz, S. Mackiewicz Department of Immunology and Rheumatology, Medical Academy, Poznan, Poland J.A. Kint, J.G. Leroy Department of Pediatrics, Medical School, Gent State University, Belgium I. Vandermeulen I.W.O.N.L. - Belgium
Introduction Serum amyloid P component (SAP), a human serum protein with a molecular weight of 230.000 daltons, consists of 10 identical subunits. The latter polypeptide chains are arranged in two parallel rings, resulting in a regular pentagon (1). Calcium dependent binding to agarose was among the first described proporties of SAP (2). This binding has recently been shown to be due to the presence of pyruvated galactose in the agarose preparation (3). SAP is also identical to Clt, one of the lesser known factors in the complement chain (4). The exact amino acid sequence of human SAP is known (5). Although it has been surmised that human SAP is a glycoprotein (6), no experimental data about its carbohydrate content have been published. The present study is a first attempt towards obtaining some information on the identity and structural features of human SAP. Affinity electrophoresis with lectins as ligands is a reliable method for the detection of carbohydrate residues in proteins and for discovering microheterogeneity in a class of glycoproteins (7) (8).
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
118
Material and Methods Reagents : Electrophoretic buffers : Veronal Calcium (pH = 8 , 6 0,025 ionic strength). Tris-EDTA-borate (TEB) (pH = 8,6 - 0,025 ionic strenght), Agarose A (Mr = - 0.13, Pharmacia, Sweden), Agarose Janssen Chimica (Mr = - 0.10, Jansen Chimica, Belgium). Antibodies : goat antihviman SAP, IgG fraction (Atlantic Antibodies, U.S.A.) rabbit antihuman SAP gamma globulin fraction (Dako, Denmark). Lectins : soy bean agglutinin (SBA) was from Pharmacia, Sweden. Concanavalin A (Con A) was purified from jack bean by affinity chromatography on Sephadex G 75 as described (9). Lentil lectin (L.C.A.) from Lens culinaris seeds and Pisum sativum agglutinin (PSA) from garden peas were purified according to the same procedure. Solanum tuberosum agglutinin (STA) was kindly provided by Dr. E. Van Driessche (University of Brussels, Belgium). Alpha-methyl-D-mannoside (alpha MM) was purchased from Jansen Chimica, Belgium and N-acetyl-D-glucosamine from Sigma, U.S.A. Hydrolyzed agarose : 20 % agarose A was incubated in 2N HCL under nitrogen atmosphere for 4 hours at 60°C. The pH was then adjusted to 8,6 with solid Na2HP04 and concentrated NaOH. Excess of salts was removed by Amberlite Monobed MB-3 resin (B.D.H., Poole, England). Hydrolysed agarose when mixed with agarose A or agarose Jansen did not influence the electrophoretic mobility of serum proteins, as checked by zone electrophoresis. Purification of SAP : SAP was purified from pleura fluid of two adult patients suffering from lung cancer by means of calcium dependent affinity chromatography (2). Crossed Immunoelectrophoresis (CIEP) : was performed according to Axelsen et al. (10). All experiments were run in parallel in 1 % agarose Jansen and 1 % agarose A in veronal calcium and TEB buffers. Increasing amounts (0,1 % - 0,2 % - 0,4 % - 0,8 % 1,6 %) of hydrolyzed agarose were added to the first dimension gel in order to estimate the influence on SAP binding. The first dimension was run at 10 Volt-cm~l for 40 minutes, the second dimension in the antibody containing gel at 2 Volt-cm-^ for 16 hours. This second dimension gel contained 5 microliter of anti human SAP antiserum (Daka or Atlantic Antibody) per milliliter of gel. After electrophoresis the plates were pressed, dried and
119
stained with Coomassie Brillant Blue R 250 (Sigma). Affinity-electrophoresis (Aff-EP) : was performed as described by Bog-Hansen (11). All experiments were performed in 1 % agarose A and veronal-calcium buffer. The first dimension gel contained one of five lectins (Con A, L.C.A., S.B.A., S.T.A., P.S.A.) in a concentration of 1 mg per ml and - except controls - 0,4 % of the hydrolyzed agarose. The second dimension gel contained anti SAP antibodies (5 jil per ml of gel) and 10 % of alpha MM or 10 % of N-acetyl-D-glucosamine, except for the control experiment when sugars werd omitted. Electrophoresis and processing of the gel was performed as described for CIEP.
Results Crossed immuno-electrophoresis Non purified pleura fluid SAP is resolved into a retarded and a non-retarded fraction when a Veronal-calcium buffer is used. The resolution into two fractions of crude pleura liquid SAP was seen in agarose A, but not in agarose Jansen (Figure 1).
1A
1B
Figure 1. - Crossed immuno electrophoresis of SAP from pleura fluid in Veronal-calciumbuffer. First dimension:l % agarose without any addition. Second dimension:1 % agarose with anti SAP antiserum (see material and methods). A = agarose A; First dimension : Ca+2-Veronal buffer. B = agarose Jansen; First dimension : Ca+2-Veronal buffer.
120
Purified SAP does not show any precipitate in the second dimension of agarose Jansen. In agarose A however, an elongated precipitate appears (Figure 2 A). Upon addition of increasing amounts of hydrolyzed agarose in the first dimension gel in veronal calcium buffer (agarose A), the migration of purified SAP increases (figure 2). In CIEP with agarose Jansen, hydrolyzed agarose causes the appearance of a SAP-anti SAP precipitate as well as changes in the SAP mobility similar to those observed with agarose A.
2A
29.
Figure 2. - Crossed Immunoelectrophoresis of purified SAP in agarose A. First dimension : increasing amounts of hydrolyzed agarose. A = control, without hydrolyzed agarose. B = 0,1 % hydrolyzed agarose. C = 0,2 % hydrolyzed agarose. D = 0,U % hydrolyzed agarose.
In control experiments with either purified or non-purified SAP in TEB buffer, always a single peak of SAP with alpha-1-mobility is obtained in agarose A or in agarose Jansen. Affinity electrophoresis Free Con A in the first dimension gel (Figure 3). Non-purified SAP yields a low peak at the position of the too of the affinity precipitate when alpha MM is omitted from the second dimension gel. In the experiment with purified SAP no affinity precipitate in the first dimension and no SAP anti-SAP precipitate
121
in the second dimension gels are seen. Addition of 10 % alpha MM to the second dimension gel causes the appearance of two SAP peaks : variant 1 is retarded while variant 2 precipitates at the application well. The retardation of variant 1 and the relative amount of variant 2 increases while the relative amount of variant 1 decreases with an increase of the Con A concentration. Other lectins Application of LCA, SBA, PCA and STA in affinity electrophoresis does not result in any ratardation of the SAP migration or in its precipitation during the first dimension run. However, when non-purified SAP was examined, affinity precipitates with other glycoproteins appear with LCA and PSA.
3A
Figure 3. -
3B
Con The A = B = C = The and
3C
A affinity electrophoresis of purified SAP. first dimension gel contains con A : 0,125.10-5M 0,250.10-5M 0,500.10-5M second dimension gel contains anti SAP antiserum (0,5 10 % alpha-methyl-manno side.
Discussion 1. Calcium dependent interaction between agarose and SAP. The property that SAP binds strongly to agarose has been used for its affinity purification (2). Our results confirm the
122
conclusion of others (1) that the quality of the agarose itself is an important factor for the binding of SAP : the higher the pyruvate content of the agarose, the higher its binding capacity for SAP (3). In the agarose from one manufacturer (Pharmacia) about 50 % of the SAP gives an interaction with the agarose, while in the agarose from the other manufacturer almost 100 % of the SAP is retarded (Fig. 1A-1B). However this interaction is mucht stronger for purified SAP than for SAP in crude pleura fluid. 2. Interaction between SAP and lectins. Human, mouse and rat SAP are all glycoproteins, but their exact carbohydrate composition has not yet been determined (6). The carbohydrate moieties of plaice SAP have been identified : 3 mannose, 2 galactose, 3 N-acetylglucosamine and 2 sialic acid residues per glycosylated polypeptide subunit. Our findings indicate that among 5 lectins with different sugar specificity only Con A showed an interaction with SAP. Suprisingly, two other lectins with similar specificity (LCA and PSA) did not show any SAP binding, although both lectins produced a clearly visible affinity precipitate with the other glycoproteins present in the pleura fluid. As has been shown by Debray et al. (12) lectins with D-mannose specificity can recognize fine differences in more complex carbohydrate structures. Different microheterogeneity pattern have been found when analyzing alpha fetoprotein in affinity electrophoresis with Con A and L.C.A. (7). Studies of alpha-l-acid glycoprotein revealed 3 variants of this glycoprotein in affinity-electrophoresis with Con A where as the same technique with L.C.A. gave no interaction at all between the lectin and the glycoprotein (Kint, unpublished results).
123
References 1. Painter, R.H., I. De Escallon, A. Massey, L. Pinteric, S.B. Stern. 1982. In : "C-reactive Protein and the plasma protein response to tissue in jury". (I. Kushner, J.E. Volanakis and H. Gewürz, eds.). Annals of the New York Academy of Sciences 389, 199-215. 2. Assimeh, S.N., D.H. Bing, R.H. Painter. 113, 225-234.
1974.
J. Immunol.
3. Hind, C.R.K., P.M. Collins, D. Renn, R.D. Cook et al. J. Exp. Med. 15j), 1058-1069. 4. Painter, C.H.
1977.
1984.
J. Immunol. 119, 2203-2205.
5. Anderson, J.K., J.E.M. Mole. 1982. Ann. N.Y. Acad. Sei. 289, 216-223. J.A. Taylor, 1983. Ph.D. Thesis, University of London. 6. Baltz, M., F.C. de Beer, A. Feinstein, E.A. Munn, C.P. Milstein, T.C. Fletcher, J.F. March, J. Taulor, C. Bruton, J.R. Clomp, A.J.S. Davies, M.B. Pepijs. 1982. Ann. N.Y. Acad. Sei. 389, 49-74. 7. Mackiewicz, A., J. Breborowicz. 1981. In : "Lectins-Biology, Biochemistry, Clinical Biochemistry". (T.C. Bog-Hansen, ed.), (W. de Gruyter, publisher), 1, 315-326. 8. Bog-Hansen, T.C., K. Takeo. 67-71.
1980.
J. Electrophoresis 1,
9. Entlicjer, G., J.V. Kostir, J. Kocourek. Biophys. Acta 221, 272-281.
1970.
Biochim.
10. Axelsen, N.H., E. Bock.
1972.
11. Bog-Hansen, T.C.
Anal. Bioch. 56, 480-488.
1973.
J. Immunol. Methods 1, 109.
12. Debray, H., D. Decout, G. Stecher, G. Spik, J. Montreuil. 1981. Eur. J. Biochem. 117, 41-55.
A NEW BINDING SPECIFICITY FOR SERUM AMYLOID P COMPONENT ITS P R A C T I C A L A P P L I C A T I O N S
D . S e r b a n and
AND
Ch.Rordorf-Adam
P h a r m a D i v i s i o n , R - 1 0 5 6 . 1 . 7 8 , C i b a - G e i g y L t d . , 4002 Switzerland
Basel,
Int roduct i on Serum amyloid P-component protein
(SAP) is the c i r c u l a t o r y
S A P is a normal
serum p r o t e i n in h u m a n s ,
s l i g h t l y r i s i n g in i n f l a m m a t i o n an a c u t e - p h a s e
reactant
its
(1), w h e r e a s
in the m o u s e
(3, 4). R e c e n t l y ,
it b e h a v e s
like
(2).
in a
C^-binding
calcium-dependent
the c a r b o h y d r a t e m o i e t y of
r e c o g n i z e d b y S A P has b e e n i d e n t i f i e d W e have r e p o r t e d that
the
(AP).
concentration
It has b e e n shown that S A P b i n d s to f i b r o n e c t i n , p r o t e i n , e l a s t i n fibers and a g a r o s e manner
form of
found in a m y l o i d d e p o s i t s , a m y l o i d P - c o m p o n e n t
agarose
(5).
(TNP)-conjugated proteins 2+ are r e c o g n i z e d b y b o t h h u m a n and m o u s e S A P in a C a -depending
reaction
trinitrophenyl
(6). B a s e d on this i n t e r a c t i o n we d e v e l o p e d a s e n s i -
tive E L I S A
for the d e t e c t i o n of SAP.
Result s P u r i f i e d SAP (human or m o u s e ) depending manner,to
bound,
in a
concentration-
i n s o l u b i 1 i z e d T N P - K L H . T h e S A P b o u n d to
the T N P - K L H w a s d e t e c t e d by indirect E L I S A , w e l l s sequentially
i n c u b a t e d w i t h rabbit
horseradish peroxidase
being
anti-SAP antiserum
linked a n t i - r a b b i t
s e n s i t i v i t y of the assay w a s 0.6 ng/ml
and
IgG c o n j u g a t e .
SAP.
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
The
126 T h e b i n d i n g of SAP to T N P - K L H w a s chelator
inhibited by a calcium
(EDTA), by p e c t i n , a g a l a c t o s e - r i c h
polysaccharide,
b y K L H and T N P - K L H a n d b y two soluble h a p t e n s ,
phosphorylcho-
line and p - a m i n o p h e n y l a r s o n i c acid. S u r p r i s i n g l y , p i c r i c was a weak
inhibitor
(Table
acid
1).
Table 1 I n h i b i t i o n of P u r i f i e d M o u s e SAP B i n d i n g to
Insolubi1ized
TNP-KLH Inhibitor
C o n c e n t r a t i o n at inhibition
picric acid phosphory1cho1ine p-aminophenylarsonic pect i n KLH
22.0
x 10
4.6
x 10
_3 _3 _3
0.13 x 10
a
1 . 0 x 1 0 ®
3
2.5
TNP-KLH a
acid
half-maximum
(M)
a
x
10"8
0.86 x 1 0 ~ 8
B a s e d on a m o l e c u l a r w e i g h t of 25,000 d (pectin), (KLM) and 43 T N P m o l e c u l e s
In o r d e r to test the a s s a y
100,000
for the d e t e c t i o n of
unpurified
SAP, two g r o u p s of five C 5 7 B L / 6 m i c e w e r e
i n j e c t e d i.p. w i t h
e i t h e r saline or 10 ug LPS. A f t e r 48 hrs,
the m i c e w e r e
b l e d a n d the 10 samples, d i l u t e d 1:2500, w e r e a s s a y e d S A P on insolubi1i zed T N P - K L H . T h e results
(Table 2)
that our E L I S A s y s t e m can be u s e d for d e t e c t i o n of mouse
SAP.
d
/ 100,000 d K L M
for
indicates unpurified
127 Table 2 P r e s e n c e of T N P - B i n d i n g S A P in C 5 7 B L / 6 SAP3
Treatment none LPS a
Serum
25 ±
3 |ig/ml (0,.39 ± 0. 13)
100 ± 10 ug/ml
(1.. 65 ± 0.36)
The v a l u e s g i v e n are the a v e r a g e s of 5 d i f f e r e n t C57BL/6
samples of
s e r u m tested ± s t a n d a r d d e v i a t i o n . T h e v a l u e s
in b r a c k e t s represent
given
OD^g2>
We
found that u n p u r i f i e d h u m a n SAP w a s also e a s i l y 4 d e t e c t e d even at a 1:10 d i l u t i o n of serum (to be r e p o r t e d e1sewhere).
T h e T N P - s p e c i f i c i t y of SAP w a s
further d e m o n s t r a t e d b y
affini-
ty c h r o m a t o g r a p h y on T N P - S e p h a r o s e . The p a s s a g e of b o t h h u m a n 2+ and m o u s e serum, in the p r e s e n c e of C a , through TNP-columns, removed more
than 90 % of the a p p l i e d SAP
(6).
1. P e p y s , M . B . et al., 1978. N a t u r e 273,
168.
2. P e p y s , M . B . a n d M . L . B a l t z ,
Immunol. 34,
Re ferences
1983. A d v .
3. de B e e r , F . C . , M . L . B a l t z , S . H o l f o r d , A . F e i n s t e i n M . B . P e p y s , 1981. J. Exp. M e d . 154, 1134. 4. P e p y s , M . B . et al., 1977. Lancet
1,
5. H i n d , C . R . K . et al. 1984. J . E x p . M e d . 6. S e r b a n , D . and C h . R o r d o r f - A d a m , Bi o c h e m .
141.
and
1029. 159,
1058.
1985, s u b m i t t e d to A n a l .
STRUCTURE AND FUNCTION OF SAA
M.D. Benson, F.E. Dwulet, B. Kluve-Beckerman, M. Aldo-Benson Department of Medicine, Indiana University School of Medicine Indianapolis, Indiana 46223
Introduction Serum amyloid A (SAA) is an acute phase protein which is synthesized by the liver and secreted into the plasma where it circulates as part of the high density lipoprotein (HDL) complex (1,2,3). Normally it is present in plasma in concentrations around 1 to 4 ug/ml, but during times of inflammation, either acute or chronic, the plasma SAA level may rise to 300 to 500 yg/ml. This acute phase response is associated with synthesis of specific mRNA for SAA by hepatocytes (4) and is under the control of interleukin 1 (IL 1) or a similar monokine that is produced by monocyte/macrophages. This mechanism of protein synthesis induction appears to be the same for C—reactive protein (CRP) and probably alpha 1 acid glycoprotein (6). These proteins stand apart from other acute phase reactants by the magnitude of their response to inflammation. It is this unique response that makes these proteins of great interest to the student of inflammatory processes and at the same time raises questions about their importance in the biological mechanisms of response to injury. To solve some of these problems we have studied SAA at the primary structure level and searched for presumptive biologic functions in the immune system.
Structure of SAA Protein AA is the major constituent of secondary (reactive) amyloid, and this has allowed isolation of the protein in sufficient quantities to do structural analyses. The complete amino acid sequence of amyloid protein A (AA) was first reported by Levin et al. in 1972 (7) (Figure 1). Since that time a few AA
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
130
proteins have been completely sequenced but not enough data are available to analyze the heterogeneity that probably exists. In 1982 Parmelee et al. reported the entire sequence of SAA which is a single chain polypeptide with 104 amino acid residues (8). The first 76 amino acids are homologous to AA and it is presumed that AA is a degradation product of the serum protein. Two amino acids were found at positions 52 and 57 of SAA isolated from pooled serum suggesting that there are at least 2 gene products in the serum during acute phase response. Work by other authors has shown as many as 6 species of SAA when isolated by ion exchange chromatography (9). It would appear that much of this heterogeneity is explained by variations at the amino terminal end of the SAA molecule. It is now recognized that while human protein AA has an arginine amino terminus, a sizeable fraction of the serum protein has a serine amino terminus (position 2) and indeed a smaller fraction has phenylalanine at the amino terminus (position 3). It is not yet clear whether this represents different gene products or represents a post translational modification of the molecule. Studies at the gene level will probably be required to answer this question. SAA has been identified in a number of species and most of these species have been shown to develop reactive amyloidosis. Primary structure analysis of human, monkey, mink and guinea pig AA proteins has shown a striking degree of homology particularly in the portion of the molecule from residue 35 through 60 (10,11,12). To study this in more depth we have undertaken a phylogenetic analysis of the AA proteins and isolated amyloid protein AA from the CBA/J mouse, the Abyssinian cat, and spontaneous amyloid in the dog. Comparison of these structures to the data known for human, monkey, mink and duck amyloid protein AA has confirmed the conservation of homology in the region from residues 35 through 60 (13,14,15,16) (Figure 1). At the same time the amino terminal and carboxyl terminal portions of the molecule show heterogeneity among species suggesting normal phylogenetic divergence. The fact that there is a strongly conserved region of the SAA molecule suggests that there is an important function for the protein. This important function has not been obvious.
131
to
3-J mo i
< 9 «
< -I z _J < 9
3 < te.
a. t-
o < J
Ul X C L
• 1 1
SÉ
< 9 oc
< > C 9 < 9
>-
«9
< 9 I < 9 < E < 3
K 1>a. a. Ul _J « ce (9 t>z z -1 o < 9 19 «9 •
< > < >
< >
i/i u> v> >->->-
-I -1 -I
UI a
•
3
< « m LU Ul Ui je X K ) Z o t- Z z V 3 (J S 8 < 3 o 3 X £ Q u £ (9 £ a
w
3 < i -I 0 1 3
Z 2 J in w «o < < i i i w n M b J > >-i _i i c e > -
*
•
• >-
V)
3
(9 a< c
3
0.40
;'
0.500
C
i
1
1
0.250
1
Z
o 5
¡E
z UJ
o z o U
1 CM r rH
rH m m
1
r~l CM
in (N
1 rH
m VD 00 i CM CM rH
0
ra : Ol •H a 3 ra = u a) >
(0 o •H
! 8
ja 10 H
C
O o
4-1 o rH (0 s
a; 4-1 10
4-1 0 Í-H 10
4-1 O
•S1 a ra 3 ra Ih (U >
o V4 4-1 =
C O u
1
s (0 O 1-i 4-1
"8
8>
c
£
c
485
Fig. 2: Effect of malotilate on hepatic alterations induced by repeated pig serum injections in the rat
Fig. 2a: Liver section from control rat, treated with malotilate (100 mg/kg) for 10 weeks. (HE stain x 160)
Fig. 2b: Liver section from pig serum intoxicated rats for 10 weeks showing connective tissue septa linking portal tracts and central veines. (HE stain x 160)
Fig. 2c: Liver section from pig serum and malotilate (20 mg/kg) treated rats. Neither septal fibrosis nor necrosis was observed. (HE stain x 160)
486 Discussion
20 injections of pig serum produced marked hepatic fibrosis in the rat, as shown by both biochemical and histological examinations. This appeared in the absence of large hepatocellular damage. Our results are in accordance with previous data [12]. Malotilate treatment prevented almost completely the development of fibrosis and the impairment of hepatic excretion function. The two dosages (20 and 100 mg/kg) were almost equally effective.
The hepatic fibrosis described in animals chronically immunized with pig serum may be an example of immune complex mediated collagen deposition [13]. A type III immune reaction would occur when soluble antigens combine with antibody to form immune complexes in either the interstitial space or the intravascular space, then the inflammatory response would trigger the collagen deposition in the liver.
The inhibitory effect of malotilate on fibrogenesis could be mediated through an action on the immune system, the inflammatory response and/or the collagen metabolism.
No data are yet available concerning the effect of malotilate on the immune system. Regarding its effect on the inflammatory stage, malotilate inhibited specifically the in vitro proliferation of liver connective tissue cells, isolated from fibrotic livers of patients with severe schistosomiasis [14]. Preliminary experiments on human embryo fibroblast chemotaxis, using fibronectin as chemoattractant
[15], suggested that malotilate decreased the
fibroblast migration. These results are interesting since the
487 relationship between connective
tissue c e l l s and f i b r o n e c t i n , as a
c h e m o t a c t i c factor, has b e e n p o s t u l a t e d [16]. M a l o t i l a t e c o u l d t h e r e f o r e
in the pig s e r u m m o d e l
interfere o n the
r e s p o n s e and e s p e c i a l l y o n the c e l l s i n v o l v e d p r o c e s s by d e c r e a s i n g unlikely synthesis
inflammatory
in the
fibrogenic
their migration and/or proliferation.
that m a l o t i l a t e
i n t e r f e r e s d i r e c t l y w i t h the
It is
collagen
in the n o r m a l s i t u a t i o n . In v i t r o , m a l o t i l a t e had no
s p e c i f i c e f f e c t on c o l l a g e n b i o s y n t h e s i s skin fibroblasts;
nor d i d it m o d i f y ,
in c u l t u r e s of
in young g r o w i n g
normal
rats,
the
h y d r o x y p r o l i n e c o n t e n t of skin, lung or liver, n e i t h e r the d a i l y u r i n a r y e x c r e t i o n of h y d r o x y p r o l i n e
[17].
The m e c h a n i s m of a c t i o n of m a l o t i l a t e
r e m a i n s u n c l e a r , but our
e x p e r i m e n t has b r o u g h t new insight into the e f f i c a c y of the d r u g : it is d e m o n s t r a t e d that m a l o t i l a t e p r e v e n t s the d e v e l o p m e n t of hepatic fibrosis
in two e x p e r i m e n t a l m o d e l s
m e c h a n i s m s : CCl^
(necrosis) and pig serum
induced by
(immune reaction)
does not require m e t a b o l i c a c t i v a t i o n and i n v o l v e s only n e c r o s is.
different which
few cell
488
References 1.
Kitagawa, H., Saito, H., Sugimoto, T., et al. Effects of diisopropyl-1.3-dithiol-2-ylidene malonate (NKK-105) on acute toxicity of various drugs and heavy metals. J. Toxicol. Sei. 7, 123-134 (1982).
2.
Younes, M. and Siegers, C.P. Effect of malotilate on paracetamol induced hepatotoxicity. Tox. Letters 25, 143-146 (1985).
3.
Sugimoto, T., Imaizumi, Y. and Kasai, T. Treatment of carbon tetrachloride fatty liver with diisoproply-1.3 dithiol-2-ylidene malonate (NKK-105). Japan. J. Pharmacol. 28, 126 (1978).
4.
Dumont, J.M., Maignan, M.F., Herbage, D. and Perrissoud, D. Effect of malotilate on carbon tetrachloride induced liver injury in the rat. EASL Satellite Symposium, Bern, 1984.
5.
Zimmerman, H.J. Experimental hepatotoxicity. In: Experimental production of diseases, part 5, Liver, ed. D. Eichler, Springer-Verlag, Berlin-Heidelberg-New York, 1976.
6.
Tamayo, R.P. Is cirrhosis of the liver experimentally produced by CC1. an adequate model of human cirrhosis. Hepatology, 3, 112-120 (1983).
7.
Parronetto, F. and Popper. H. Chronic liver injury induced by immunologic reactions. Am. J. Pathol. 49, 1087-1101 (1966).
8.
Folch, H., Lees, M. and Stanley, G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497-510 (1957).
9.
Prockop, D.J. and Udenfriend, S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal. Biochem. 1, 228-239 (1960).
10
Perrissoud, D. L'electrophorese en gel de Polyacrylamide. In: New Trends in the therapy of liver diseases. Int. Symp. Tirrenia, 1974, pp. 38-54, Karger, Basel, 1975.
11. Heath, D.F. Normal or log-normal: appropriate distributions. Nature, 213, 1159-1160 (1967). 12. Ballardini, G., Esposte, F.D., Bianchi, F.B. et al. Correlation between Ito cells and fibrogenesis in an experimental model of hepatic fibrosis. A sequential stereological study. Liver 3, 58-63 (1983). 13. Thomas, H.C. Immunological aspects of hepatic fibrosis. Ital. J. Gastroenterol. 12, 33-36 (1980).
489 14. Borojevic, R., Vinhas, S.A., Domont, G.B. and Grimaud, J.A. Effect of malotilate on human connective tissue cells in vitro. EASL Satellite Symposium, Bern, 1984. 15. Mensing, H., Pontz, B.F., Muller, P.K. and Gauss-Muller, V. A study on fibroblast Chemotaxis using fibronectin and conditioned medium as chemoattractants. Eur. J. Cell. Biol. 29, 268-273 (1983). 16. Cenacchi, G., Ballardini, G., De Giorgi, L.B. et al. Relationship between connective tissue cells and fibronectin in a sequential model of experimental hepatic fibrosis. Virchows Arch. (Cell Pathol.) 43, 75-84 (1983). 17. Ryhanen, L. and Hamalainen, I. Effect of malotilate on the metabolism of collagen. EASL Satellite Symposium, Bern, 1984.
DEVELOPMENT OF FIBROSIS IN HEPATIC ALVEOLAR ECHINOCOCCOSIS A SEQUENTIAL STUDY IN MICE INFECTED WITH ECHINOCOCCUS MULTILOCULARIS
D.A. Vuitton, Van-Pierre Tran
Service d ' H é p a t o l o g i e , CHU, F-25030 Besançon cedex F r a n c e
S. G u e r r e t - S t o c k e r , J.A. Grimaud Laboratoire
de
Pathologie
Cellulaire
du
Foie,
CNRS
ERA
819,
Institut
Pasteur,
F-69365 Lyon cedex 7, F r a n c e M. Liance, R. Houin
L a b o r a t o i r e de Parasitologic, CHU, F-94010 C r e t e i l cedex F r a n c e
Introduction A dense fibrosis destroying normal s t r u c t u r e s of t h e liver is one of t h e of
human
h e p a t i c alveolar
hallmarks
echinococcosis (AE). This very s e v e r e p a r a s i t i c
disease
is due to t h e development in t h e liver of t h e larval f o r m of t h e c e s t o d e Echinococcus
multilocularis (Em). The p a r a s i t i c development
is a s s o c i a t e d
to an
important
g r a n u l o m a t o u s response of t h e host and an intense fibrogenesis which is responsible for the main complications of t h e disease, such as bile duct obstruction and p o r t a l hypertension. Immunopathological studies in human AE (1) suggest t h a t a) t h e development of fibrosis is r e l a t e d to t h e immune response of t h e host, mainly at the b o r d e r line b e t w e e n
granuloma
and
normal
liver
parenchyma,
and
b) increased
fibroge-
nesis is present in t h e e n t i r e liver, even in a r e a s d i s t a n t from t h e foci of p a r a s i t i c lesions. Various species- and strains- r e l a t e d sensitivities to Em have been
shown
(2, 3), and we have developed a murine model of AE in order to assess t h e r e l a t i o n ship b e t w e e n t h e cellular i m m u n e response of t h e host and t h e i n t r a h e p a t i c development of t h e Em larvae (3). Fibrogenesis could play an i m p o r t a n t role in modulating the
larval
development,
and
be directly
dependent
upon
functional activities
of
cells of t h e granuloma, and p a r t i c u l a r l y m a c r o p h a g e s . In order to p r e c i s e this r e l a tionship
between
fibrosis,
p a r a s i t e i t s e l f , a sequential
periparasitic
granulomatous
infiltration,
and
the
larval
immunopathological and q u a n t i t a t i v e study of collagen
M a r k e r Proteins in Inflammation, Vol. 3 © 1986 Walter d e Gruyter & Co., Berlin • N e w York - Printed in G e r m a n y
492 d e p o s i t s in t h e liver has b e e n p e r f o r m e d in e x p e r i m e n t a l l y i n f e c t e d m i c e of 2 inbred s t r a i n s d i f f e r i n g by t h e i r r e s p e c t i v e s e n s i t i v i t y and r e s i s t a n c e to Em.
M a t e r i a l and Methods Animals Mice of t h e inbred s t r a i n s AKR and C57BL10 w e r e used for this study ( I F F A - C R E D O L ' A r b r e s l e , F r a n c e ) . These t w o s t r a i n s h a v e been previously shown t o be " s e n s i t i v e " and " r e s i s t a n t "
to
Em g r o w t h
was p e r f o r m e d by d i r e c t previously
described
intrahepatic
injection
respectively
intrahepatic
in d e t a i l (3). C o n t r o l of
saline,
with
(3) (fig
1). I n f e c t i o n with
Em
larvae
i n j e c t i o n , under l a p a r o t o m y , as it has the
m i c e of same
the same
surgical
strains
procedure.
been
received Autopsies
5 m i c e of e a c h s t r a i n and t h e i r c o n t r o l s w e r e p e r f o r m e d a f t e r 7, 20, 30, 60, and
180 days
of
i n f e c t ion.
In t h e
"resistant"
C57BL10
strain,
additional
an of 120
studies
w e r e p e r f o r m e d on t h e 270th d a y . The liver was r e m o v e d and w e i g h t e d a f t e r m a c r o scopical
examination.
apparently
"normal"
Samples areas,
of
were
liver, frozen
taken in
from
liquid
parasitic
nitrogen
and
lesions
and
stored
at
from -80°C.
Fig 1. Histological a s p e c t s of t h e lesions observed in t h e liver, on t h e '/th m o n t h a f t e r i n f e c t i o n with Em l a r v a e ; a) in AKR m i c e . Epithelioid cells (EC) a r e lining t h e g e r m i n a l layer (arrow) of a l a r g e p a r a s i t i c v e s i c l e (PV) (Masson's t r i c h r o m e x 625). b) in C57BL10 m i c e . An i m p o r t a n t a r e a of n e c r o s i s (N) is surrounding t h e g e r m i n a l layer (arrow) of a small PV. ( H e m a t o x y l i n - E o s i n - S a f r a n ; x 625). G + F = polymorphous g r a n u l o m a and fibrosis.
493 I m m u n o f l u o r e s o e n c e s t u d i e s with a n t i - c o l l a g e n t y p e s a n t i s e r a .
Polyclonal
monospecific antibodies against
t y p e I, III and IV c o l l a g e n s ,
propeptide
III, f i b r o n e c t i n and laminin w e r e used on 5 Jim thick u n f i x e d f r o z e n liver s e c t i o n s . P r e p a r a t i o n and p u r i f i c a t i o n of t h e m o n o s p e c i f i c a n t i b o d i e s a r e d e s c r i b e d (U, 5). F l u o r e s c e i n Pasteur,
France)
isothiocy a n a t e or
rabbit
(FITC) labelled
anti-goat
IgG
(Nordic,
sheep anti-rabbit Tilburg)
elsewhere
IgG
(Institut
immunoglobulins
used, a c c o r d i n g t o t h e origin of t h e m o n o s p e c i f i c a n t i s e r u m , a t
were
1/20 dilution. All
readings w e r e p e r f o r m e d on a L e i t z - D i a l u x f l u o r e s c e n c e m i c r o s c o p e .
Quantitative
determination
of
collagen-protein
and
total-protein
c o n t e n t on
liver
sections. The
micromethod
for
determination
of
the
total-
and
collagen—protein
content
in p a r a f f i n e m b e d d e d h u m a n liver s e c t i o n s d e v e l o p e d by Lopez de Leon and Rojkind (6) was
adapted
performed
to
on two
frozen 10 p m
sections
of
mouse liver.
Briefly, determinations
thick f r o z e n liver s e c t i o n s . P a r a s i t i c a r e a s ,
were
apparently
" n o r m a l " liver of i n f e c t e d m i c e , and liver of c o n t r o l m i c e w e r e a n a l y s e d
respecti-
vely. Slides w i t h liver s e c t i o n s w e r e i n c u b a t e d for t w o hours in a solution of F a s t Green
FCF
and
temperature.
Sirius red F3 BA in p i c r i c acid with c o n t i n u o u s shaking a t
acid and F a s t g r e e n . The l a t t e r c o n t r o l slide was used t o c a l c u l a t e t h e of
absorbance
staining
room
Two c o n t r o l slides per s a m p l e w e r e i n c u b a t e d r e s p e c t i v e l y with p i c r i c of
Fast
was eluded
green
with
at
1 ml of
540 nm. NaOH
After
3 washings with
0.1 N (0.5 ml) and
A b s o r b a n c e was r e a d on a s p e c t r o p h o t o m e t e r
at
percentage
distilled
methanol
water,
(0.5
ml).
540 nm (red Sirius + Fas t g r e e n ,
25 - 30 %) and 605 nm ( F a s t green only). The r a t i o b e t w e e n and green allowed us t o c a l c u l a t e t h e a m o u n t of c o l l a g e n
a b s o r b a n c e s of
red
p r o t e i n (pg) per mg of
t o t a l p r o t e i n s in t h e liver s e c t i o n s . Four assays w e r e m a d e per liver s a m p l e , and t h e mean p r o t e i n c o n t e n t s w e r e o b t a i n e d f r o m 3 m i c e of t h e s a m e group.
Results
Immunofluorescence studies Seven in t h e
days a f t e r
infection,
2 s t r a i n s of
f i b r o g e n e s i s was conspicuous
mice. Concentric collagen
around
parasitic
d e p o s i t s w e r e heavily
vesicles
labelled
with
a n t i - t y p e III p r o c o l l a g e n and t y p e III collagen a n t i s e r a . At this s t a g e , t h e p r e d o m i nant f e a t u r e was the development
of t h e f i b r o n e c t i n f r a m e w o r k , having t h e s h a p e
494
Fig 2. F i b r o n e c t i n n e t w o r k on t h e 7th day a f t e r i n t r a h e p a t i c l a r v a e a) in AKR m i c e ; b) in C57BL10 m i c e . ( x 625).
infection
with
Em
Fig 3. D e t a i l of collagen d e p o s i t s a r o u n d a large p a r a s i t i c vesicle in AKR m i c e , a t one month a f t e r i n t r a h e p a t i c i n f e c t i o n with Em l a r v a e , a) labelled with a n t i t y p e III c o l l a g e n , b) labelled with a n t i - t y p e 111 p r o - c o l l a g e n . Two main lines of deposition a r e n o t i c e a b l e : along t h e p a r a s i t i c v e s i c l e (PV), and a t t h e b o r d e r l i n e with liver c e l l s ( x 625).
495
F i g . k. Aspects of the p e r i p a r a s i t i c h e p a t i c fibrosis in C57BL10 m i c e , on the 4 t h m o n t h a f t e r i n f e c t i o n w i t h Em l a r v a e , a) L a b e l l i n g w i t h a n t i - t y p e 1 collagen a n t i serum (x 625) ; b) Vascular neogenesis in the p e r i p a r a s i t i c g r a n u l o m a : vessels are labelled w i t h a n t i - l a m i n i n a n t i s e r u m (PV = p a r a s i t i c vesicle ; x 250).
F i g . 5. C o m p a r i s o n b e t w e e n thickness of the p e r i p a r a s i t i c i n f i l t r a t e a) in A K R m i c e , on the 6 t h m o n t h a f t e r i n f e c t i o n w i t h Em l a r v a e ( l a b e l l i n g w i t h a n t i - t y p e I collagen a n t i s e r u m ) ; b) in C 5 7 B L 1 0 m i c e , on the 9th m o n t h a f t e r i n f e c t i o n (labelling w i t h a n t i - t y p e III collagen a n t i s e r u m ; PV = p a r a s i t i c vesicle ; x 625).
496 of a thin n e t m a d e of c o n c e n t r i c f i b e r s in AKR m i c e , and of c o a r s e - f i b r e d bundles in C57BL10 m i c e (fig 2 a and b). One m o n t h a f t e r i n f e c t i o n , t w o main
locations
of c o l l a g e n d e p o s i t s around p a r a s i t i c lesions w e r e o b s e r v e d in AKR m i c e : a) along t h e i n t e r n a l and e x t e r n a l sides of t h e f i r s t layer of h i s t i o c y t i c c e l l s ( t h e so-called "epithelioid cells"), lining t h e p a r a s i t i c vesicles, and b) a t t h e borderline
between
c e l l s of t h e g r a n u l o m a and p a r e n c h y m a l liver c e l l s (fig 3 a and b); t h e s e
collagen
d e p o s i t s w e r e heavily labelled with a n t i - t y p e III c o l l a g e n and p r o c o l l a g e n (no l a b e l ling with a n t i - t y p e I c o l l a g e n was o b s e r v e d in this s t r a i n ) . B e t w e e n t h e s e t w o main lines
of
collagen
deposition,
clusters
of
collagen
deposits
were
concentrically
s c a t t e r e d along t h e c e l l s of t h e g r a n u l o m a . At this s t a g e , collagen was a l r e a d y o r g a n i zed
in bundles
with anti-type
around
the
parasitic
lesions
of
I collagen (fig 4a). This l a t t e r
C57BL10
mice,
and
labelled
labelling w a s p a r t i c u l a r l y
also
important
on t h e 4th m o n t h a f t e r i n f e c t i o n in this s t r a i n , while in AKR m i c e , this was seen only on t h e 6th m o n t h . The 4th m o n t h - l e s i o n s w e r e c h a r a c t e r i z e d by a very " a c t i v e " aspect and
of
fibrogenesis
anti-laminin
in t h e
showed
an
2 strains, obvious
and
labelling
development
of
with
anti-type
vascular
IV c o l l a g e n
n e o g e n e s i s (fig
4b).
A p r o g r e s s i v e and d e f i n i t i v e e x t e n s i o n of f i b r o s i s and of p a r a s i t i c lesions was o b s e r ved in A KR s t r a i n up t o 6 m o n t h s , t h e a v e r a g e delay leading to " s p o n t a n e o u s " d e a t h f r o m t h e d i s e a s e in t h e s e m i c e . On t h e o p p o s i t e , as e a r l y as t h e 6th m o n t h , r e g r e s sion
of
fibrosis,
and
disappearance
of
type
1-collagen
was
observed
in
C57BL10
i n f e c t e d m i c e (fig 5 a and b).
D e t e r m i n a t i o n of t o t a l - and c o l l a g e n - p r o t e i n c o n t e n t . R e s u l t s of t h e q u a n t i t a t i v e analysis of fibrosis in t h e liver of i n f e c t e d and c o n t r o l m i c e of t h e 2 s t r a i n s under study a r e p r e s e n t e d in fig 6. Sham o p e r a t i o n with i n j e c tion of saline in t h e liver of m i c e w a s followed by a t r a n s i e n t i n c r e a s e of collagen p r o t e i n s which r e a c h e d its m a x i m a l value a t 2 m o n t h s in AKR m i c e and a t 1 m o n t h in
C57BL10
AKR
mice.
areas
was
mice.
This
value
A progressive observed
was
significantly
increase
in t h e
of
higher
in C57BL10
collagen-protein
2 strains a f t e r
content
intrahepatic
of
i n j e c t i o n of
mice the
than
in
parasitic
Em
larvae
:
it r e a c h e d its m a x i m a l v a l u e a t 6 m o n t h s a i t e r i n f e c t i o n in t h e 2 s t r a i n s . At this s t a ge,
collagen-protein
content
of
the
pathological
areas
was
significantly
than that observed
in t h e " n o r m a l " a r e a s of t h e liver in t h e s a m e m i c e
liver"), and
liver
the
mean
in t h e
collagen-protein
of
control content
mice of
("control
liver").
the pathological
("normal
B e f o r e t h e 6th
a r e a s w a s lower
higher month,
than
that
d e t e r m i n e d in " n o r m a l liver", or " c o n t r o l liver", but t h e d i f f e r e n c e was not significant
except
for
collagen-protein
the
1st and
2nd
months
in C57BL10
mice.
The
a m o u n t in t h e pa r a s i t i c a r e a was lower in C57BL10
mean
peak
m i c e t h a n in
of
497 AKR m i c e , but t h e d i f f e r e n c e was not s i g n i f i c a n t . The survival of C57BL10
mice
allowed us t o q u a n t i f y liver p r o t e i n - c o n t e n t a t t h e 9th m o n t h : t h e r e s u l t s showed a significant decrease assessment
obtained
collagen-protein
of c o l l a g e n - p r o t e i n c o n t e n t which c o n f i r m e d t h e q u a l i t a t i v e with
content
immunofluorescence of
"normal
liver"
study
in
(fig
infected
5b and
mice
6b). Analysis of
showed
an
increased
f i b r o g e n e s i s in t h e liver d i s t a n t f r o m t h e p a r a s i t i c lesions. In AKR m i c e , it c o n s i s t e d of
a plateau,
A spontaneous
significantly regression
higher of
than
in c o n t r o l
fibrosis, beginning
at
mice the
up t o 6 m o n t h s (fig 4th
month,
was
6a).
observed
in t h e "normal liver" of i n f e c t e d C57BL10 m i c e (fig 6b).
Fig. 6. C o u r s e of h e p a t i c fibrosis in AKR and C57BL10 m i c e ( r e s p e c t i v e l y s i t i v e " and " r e s i s t a n t " to Em) and their s h a m - o p e r a t e d c o n t r o l s .
"sen-
498 Discussion
This
sequential
that
a
study
strong
and d e v e l o p m e n t dary
immune
granuloma
present
in
studies to
The the
as
a
along main
the
the
first
hypothetical
sequence
deposition
granulomas of
("loose
fibrosis
with
connective
experimental
showed
hours of
of
of
and
events
type-Ill
bundles
on
days
of
the
matrix
type-I
It
their
suggests
internal
the
hypothesis
(7).
However,
the
amorphous
side, of
lack
nature
labelling
of
a
non-specific
been
obtained
the
mouse
this
area
of
of of
this
with
foci
an
to confirm
increased of
sections appeared of
fibrosis
in c o n t r o l matory "normal"
of
with has
in t h e
be
antiserum
aspects
was
shown
anti-laminin
in
layer
location, A
( f i g ¿ib) ;
binding
of
Em
AE
(8)
liver
in
in
the
antiadsor-
IgG. the
(1).
development
in
the
The
infection
liver.
infected
have
;
could have been
of
fibrosis
in h u m a n
entire
liver,
micromethod
was
particularly
AE which suggested in
for
portal
spaces
protein
interesting, the
distant
measurement
in
mice.
An
increased
fibrogenesis
presence from on
However,
mice
was
collagen-protein
higher,
and
its
peak
content was
of
the
delayed
the
liver-
evolution
was
observed
m i c e ; t h i s s u g g e s t s t h a t s h a m - i n j e c t i o n w a s f o l l o w e d by a d i s c r e t e
reaction
how-
host-IgG
to be r e l i a b l e and quite s u i t a b l e to study sequentially the
after
and
frequent
antibodies
experimental
antiserum,
at
laminated
observed
The
layer",
favor
explained.
these
murine fibrosis.
could
particular
because
:
the
("dense
in of
"laminated
be
(1) of
area
fibrosis
the
to
the
remodelling
central
the
and
AE
periphery
subsequent
of
Earlier
performed
human
the
liver
already
confirmed
These
mouse-laminin.
previous observations
lesions
a
this
remain
been
in
at
origin in
excluded
the
the
components
week
analysis of
of
host
layer
be
1st
and
Em.
fibrosis
anti-laminin cannot
should
periparasitic
of
the
of
of
cell-
of
infection.
collagen
studies
formation
about
vesicles
present
fibrogenesis
parasitic
al.
cells
in t h e e a r l y d e v e l o p m e n t
layer
laminated
the
parasitic
Quantitative assessment in o r d e r
et
immunization
antibodies,
the
remodelling
b e d on t h e s e p a r a s i t e - b o u n d
of
to
germinal
labelling
after
surface IgG
the
Mehlhorn
the
ever,
to
contribution
lining
after
the
the
the
the role of "epithelioid cells",
also
after
cells, secon-
due to a
of
borderline
day
sequential
AE demonstrated
their
the
procollagen
in
Moreover,
fibrosis
inoculation
organization"),
hypothesis
type-I collagen, were
different
from
and
collagen
liver
at
the
murine intrahepatic
involvement
7th
Em
the
suggested
organization").
and
made
collagen
of
except
after of
observations
connective
matrix
vesicles,
appearance
The
model
particular
of collagen,
granulomas
confirmed
immunocompetent
t h e value of
the
parasitic
AE
peri-parasitic
experimental
It
the
sequences
fibronectin.
early
in
between
components
particularly
an
useful
peri-parasitic
during
assess
exists
reaction.
located
parenchyma.
fibrogenesis
o f f i b r o s i s . It s u b s t a n t i a t e d
echinococcosis
mediated
of
relationship
inflam-
apparently in
C57BL10
499 mice,
as c o m p a r e d
to that
A significantly increased
observed
in c o n t r o l
m i c e of t h e s a m e s t r a i n (fig 6b).
f i b r o g e n e s i s in t h e " n o r m a l " liver
was o b s e r v e d on
the
6th month in t h e AKR m i c e only ; a t this s t a g e , it r e t u r n e d t o n o r m a l values in C57BL10
mice.
This d i f f e r e n c e suggests t h a t
a persistent
f i b r o g e n e s i s in
"normal"
p o r t a l s p a c e s was only observed when a s i g n i f i c a n t p a r a s i t i c mass - and a s i g n i f i c a n t g r a n u l o m a t o u s i n f i l t r a t e - w e r e still p r e s e n t in t h e liver. In f a c t , t h e main i n t e r e s t of our r e s u l t s c o n s i s t e d of t h e d i f f e r e n t c o u r s e s of fibrosis in t w o s t r a i n s of m i c e d i f f e r i n g by t h e i r r e c e p t i v i t y t o t h e Em l a r v a e . C o m p a r i s o n of quantitative of
lower
month,
data
showed
intensity
were
in C57BL10
also
f i b r o g e n e s i s of
that
lower
the
initial
collagen
mice.
The
in this s t r a i n
deposition
maximal
than
in AKR
C57BL10 s t r a i n a p p e a r e d
in
parasitic
values,
observed
mice.
However,
areas on
was
the
6th
capacity
t o be higher than t h a t of t h e
of
AKR
s t r a i n . This was d e m o n s t r a t e d by t h e c o l l a g e n - p r o t e i n c o n t e n t of t h e " n o r m a l liver" of
these
mice
after
i n f e c t i o n or s h a m - o p e r a t i o n .
Moreover,
they w e r e
noticeable
q u a l i t a t i v e d i f f e r e n c e s when t h e 2 s t r a i n s w e r e c o m p a r e d : c o l l a g e n - b u n d l e - f o r m a tion
and r e m o d e l l i n g
mice,
while
as e a r l y and
as
the
definitive
exhibited
of
thickness 4th
type-I
to
collagen
the
month.
deposition
a regressive
of
fibrosis with
of
collagen.
in f i b r o g e n e s i s ,
AKR
of
and
could
be
of
mice exhibited
type-I
collagen.
observations deposition, different
collagen
and
f i b r o s i s with e a r l y
These
synthesis
type-I
granuloma-
On
suggest
in t h e
deposits-
an e x t e n s i v e the
formation
and/or
occurred earlier
collagen
that
other immune
2 strains.
reduced late
C57BL10
of
earlier
mice
disappearance
mechanisms
activity
The
C57BL10
f i b r o s i s with
hand,
but s u b s e q u e n t
functional
in was
cells
leading involved
development
of
a w e l l - o r g a n i z e d fibrosis could be p a r t i a l l y responsible for t h e l i m i t a t i o n of p a r a s i t i c growth to
be
in
the resistant
stronger
foot-pad
C57BL10 s t r a i n .
in this
viewed and
as
schistosomiasis
of
compared
shown
(10).
The
to that respective
observed capacity
of
different
in a g r a n u l o m a t o s t i m u l a t e f i b r o g e n e s i s has r e c e n t l y been
(11). Analysis of
isolation
and
has been
mice
such
antigens
immunity
delayed-type-hypersensitivity para-
models,
Em
by t h e
in AKR
cell-types present
to
Cell-mediated
when assessed
(9). The role of lymphokines in f i b r o g e n e s i s has been e m p h a s i z e d in t h e o t h e r sitic
response
strain,
factors
t h e r e l a t i o n s h i p b e t w e e n c e l l - t y p e s and stimulating
bring m o r e p r e c i s i o n s a b o u t r e c e p t i v i t y
fibrogenesis
in
granulomatous
of t h e host and its c a p a c i t y
e f f i c a c i o u s f i b r o u s b a r r i e r a g a i n s t t h e d e v e l o p m e n t of Em.
re-
collagen-deposits, lesions
could
t o mount an
500 Acknowledgements
We wish t o
thank
Mrs Belin for m a n u s c r i p t p r e p a r a t i o n
and Mr T h i e b a u t
for
the
photomicrographs.
References
1. Vuitton, D.A., S. G u e r r e t - S t o c k e r , 3.P. C a r b i l l e t , G. Mantion, J . P . Miguet, G r i m a u d : Z. P a r a s i t e n k d . (in press).
J.A.
2. Webster, G.A., T.W.M. C a m e r o n . 1961. C a n . 3. Zool. 39, 877. 3.
Liance, M., D.A. Vuitton, S. G u e r r e t - S t o c k e r , R. Houin. 1984. E x p e r i e n t i a 40, 1436.
3.P.
Carbillet,
J.A.
Grimaud,
4. G r i m a u d , 3.A., M. D r u g u e t , S. P e y r o l , O. C h e v a l i e r , D. H e r b a g e , N. El B a d r a w y . 1980. 3. H i s t o c h e m . C y t o c h e m . 28, 1145. 5.
Linck,
G., S. S t o c k e r ,
3.A. G r i m a u d ,
A. P o r t e .
1983. H i s t o c h e m i s t r y
77,
323.
6. L 6 p e z - d e - L e 6 n , A., M. Rojkind : 3. H i s t o c h e m . C y t o c h e m . (in press). 7. Mehlhorn, H., 3. E c k e r t , R . C . A . Thompson. 1983. Z. P a r a s i t e n k d . 69, 749. 8. Ali-Khan, Z., R. Siboo. 1981. Exp. P a r a s i t o l .
159.
9. L i a n c e , M., D.A. Vuitton, D. R i v o l l e t , 3. Breuil, R. Houin : P r o c . of t h e Xlllth Int. Cong. Hydatidology (in press). 10.Wyler, D.3., S.M. Wahl, L.M. Wahl. 1978. S c i e n c e 202, 438. 11.Claman, H.N. 1985. Immunol. Today 6, 192.
INTRAALVEOLAR FIBROSIS : A REVERSIBLE FORM OF PUMONARY FIBROSIS
S. Peyrol
1
, J.F. Cordier
2
, J.A. Grimaud
1
1. Laboratoire de Pathologie Cellulaire du Foie, CNRS ERA 819, Institut Pasteur, 77 rue Pasteur, 69365 Lyon cedex 7 (France) 2. Hôpital Cardiovasculaire et Pneumoloqique Louis Pradel, 28 avenue du Doyen Lépine, Lyon (France)
Intraalveolar fibrosis has been described as a "second form of scarring" (1) in various lung disorders (idiopathic pulitDnary fibrosis, hypersensitivity pneumonia (2), histiocytosis X) and also following accidental or experimental paraquat intoxication (3). On histological sections of the lung, intraalveolar fibrosis consisted of widespread connective buds present in most, but not all, alveolar lumens, appearing as spherical nodules of variable size (50-100 n) which widened the intraalveolar spaces (fig. 1a). Recently, intraalveolar fibrosis was described as a characteristic feature of two forms or organizing pneumonia of unknown etiology, cryptogenic organizing pneumonia (COP) and bronchiolitis obliterans pneumonia ; the latter differed only by the extent of the lesions in the bronchiolar compartment. The clinical features (dyspnea, coughing, malaise, bilateral opacities on the chest X-ray's) were resolved under corticotherapy suggesting that the interstitial fibrotic lesion probably disappeared ; a relapse might be observed after stopping treatment. We studied an open lung biopsy obtained from a patient with COP during a period of relapse. Attention was focused on the connective framevrork of the intraalveolar fibrotic buds, in order to characterize the distinctive features possibly involved in the process of reversibility.
The biopsy was investigated with specific histological methods which allowed us to determine (i) the nature of the connective matrix components of the intraalveolar fibrotic buds and (ii) the pattern and organization of their deposits in relation to the cell populations involved. 1. Trichrome and Gordon-Sweets staining of paraffin embedded sections emphasized the polymorphic aspects of the intraalveolar buds ;
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
502
Fig. 1 : Intraalveolar fibrotic nodule. a. Trichrome staining ; x 675 b. Selective staining of the fibrillar connective framework (Gordon-Sweets staining) ; x 700 2. Inmunofluorescent staining on fresh frozen tissue sections allowed us to identify, in situ, immunoglobulins and the main matricial proteins (collagen types, fibronectin and laminin, proteoglycans), and also determine their relative contribution to the intraalveolar connective framework. 3. Ultrastructural observation demonstrated how the matricial conponents vrere associated into a complex connective matrix, and permitted the characterization of the cell populations involved. Intraalveolar connective buds displayed different patterns of organization from one place to the other. ALVEOLITIS was always prominent : alveolar macrophages (fig. 2a), lymphocytes and plasma cells (fig. 2b) formed large intraalveolar cell clusters where iirtnunoglobulins (mainly IgG) were present (fig. 3a) , either in the cells or localized in the extracellular space as a fluffy material (fig. 2a). At this stage, a fibrillar connective framework was appearing among immunocompetent cells, as a delicate network growing through the inflammatory focus (fig. 1b) .
503
Fig. 2 : Alveolitis. a. Alveolar macrophage ( -^h ) in alveolar lumen ; extracellular fluffy material ( 0 ), probably immunoglobulins polymers ; x 4 350 b. Plasma cells in the alveolar lumen ; x 4 200 In neighbouring intraalveolar buds, FIBROSIS probably succeeded the inflammatory stage ; conspicuous spherical fibrotic nodules consisted of a loose matricial network of fibrillar and amorphous material circumscribed and stretched by spindle-sphaped fibroblast-like cells (fig. 1a). Type III collagen (fig. 3b) and fibronectin (fig. 3c) were the main components when compared to the other matricial proteins (type I collagen, type IV collagen and laminin, proteoglycans) which had also been detected, but in smaller quantities, using monospecific inmune sera as tissular markers. In some areas of the biopsy, fibrotic nodules of neighbouring intraalveolar spaces appeared joined by fibrous connective septa leading to the formation of an extensive intraalveolar fibrotic field, and suggesting that, in a later stage, progressive confluence of the intra alveolar fibrotic buds took place by an active fibrogenetic process. In confluent fibrosis too, type III collagen (fig. 4b) and fibronectin (fig. 4a) exceeded the type I collagen.
504
Fig. 3 : Imrrtunofluorescent labeling of the intraalveolar connective bud components ; x 750 a. Immunoglobulins G-A-M b. Collagen type III c. Fibronectin
Fig. 4 : Confluent fibrotic nodules ; imrrtunofluorescent labeling of matricial components ; x 300 a. Fibronectin b. collagen type III
Fig. 5 : Intraalveolar fibrosis ; cytoplasmic process of a myofibroblast ( ) with prominent contractile filamentous apparatus ( ) ; loose extracellular connective matrix ( * ) ; x 7 500 Fig. 6 : Polymorphism of the matricial components : fibrils (1), microfibrillar clusters (2), interfibrillar meshwork (3) ; x 56 000 Fig. 7 : Myofibrocyte with prominent erqastoplasm ( ) mentous apparatus ( ) ; x 22 000
and contractile fila-
Fig. 8 : Myofibroclast ; part of the cytoplasm ; inclusions containing partially damaged collagen fibrils ( ) ; x 27 000
506 Electron microscope observation emphasized two peculiar characteristics of the CONNECTIVE MATRIX in the intraalveolar fibrotic buds (characteristics which remained unchanged in confluent fibrotic fields) : LOOSE ASPECT and POLYMORPHISM. The loose aspect, already noticed by light microscopy, appeared as an irregular arrangement of fibrillar proteins forming sinuous bundles (fig. 5). At least, three norphologically different kinds of molecular complexes were involved in this matricial arrangement (fig. 6) : collagen fibrils (types I and III), microfibrillar clusters of fibronectin and a delicate arborescent interfibrillar meshvrork, probably proteoglycans. The sinuous appearance of the extracellular connective matrix was probably related to the anchorage of the fibrillar network to the membrane and to the associated basement membrane of the unique connective cell type present in the intraalveolar fibrotic buds and septa ; this cell type was identified as MYOFIBROBLAST. These cells were recognized with their contractile filamentous apparatus associated with the cytoplasmic membrane (fig.5-7). They displayed, in various degrees, either prominent ergastoplasm (fig. 7) or multiple inclusions containing partially damaged collagen fibers (fig. 8), which probably represented the expression of the fibrocytic or fibroclastic modulation of the same cell type. Clinical evidence of complete healing with corticotherapy confirms the previous findings that such morphological features may be considered as RELEVANT SIGNS FOR THE REMODELING ABILITY AND REVERSIBILITY OF FIBROSIS (4). In conclusion, studying COP opens special investigative areas concerning : - fibrosis initiated by inflammation in response to an unknown etiologic agent, - the origin of the myofibroblastic cell line, - the significance of the matricial components' polymorphism (collagens, glycoproteins, proteoglycans...) , - the process of collagen resorption. References 1. Basset F., J. Lacronique, V. Ferrans, Y. Fukuda, R. Crystal. 1984. ftmer. Rev. respir. Dis. 129, part II, A-72. 2. Kawanami 0., F. Basset, R. Barrios, J. Lacronique, V. Ferrans, R. Crystal. 1983. Amer. J. Pathol. J_1_0, 275. 3. Fukuda Y., V. Ferrans, C. Schoenberger, R. Rennard, R. Crystal. 1985. Amer. J. Pathol. Vl8, 452. 4. Grimaud J.A., 1983. Contr. Microbiol. Immunol. 7, 190.
DISTINGUISHING PATTERNS OF ALVEOLITIS AND FIBROSIS IN HUMAN LUNG DISEASE
J.F. Cordier, S. Peyrol, C. Takiya, J.A. Grimaud, J. Brune Department of Pneuraology, Hospital Louis Pradel, 69394 LYON Cedex 3, FRANCE Department of Pathology, CNRS ERA Ö19, Institut Pasteur, 69365 LYON Cedex 7, FRANCE
Although alveolitis precedes the matricial stage of most fibrotic processes in the lung, tne cell-matrix interactions which lead from alveolitis to fibrosis vary from disease to disease. To illustrate this, we shall analyse three conditions where both the pattern of alveolitis and the site of fibrosis differ : idiopathi pulmonary fibrosis (IPF), sarcoidosis and cryptogenic organising pneumonitis (COP).
ALVEOLITIS Alveolitis consists of the accumulation within alveolar structures of immune and inflammatory cells (lymphocytes, macrophages and neutrophil polymorphs)(Fig 1). Cell-matrix interactions are mediated by the release of substances such as free oxygen radical ana proteases which can injure parenchymal cells and the connective matrix, as well as factors directing cell movement, activation or differentiation (1). Alveolitis can be stimulated by many agents including bacteria, organic or inorganic dusts, and toxic gases. Often, however, the stimulus is not known. In infectious diseases, alveolitis general
Marker Proteins in Inflammation, Vol. 3 © 1986 Walter de Gruyter & Co., Berlin • New York - Printed in Germany
508
Fig
1 - ALVEOLITIS (Sarcoidosis). Presence (M) in alveolar septum (AS). One epithelial c e l l s ( E p ) . *Alveolar
of lymphocytes (L) and lymphocyte is seen between lumen (X 7000)
Fig
2 - STRUCTURE OF THE ALVEOLAR SEPTUM. S.A. Col : collagenj Exchange zone (arrow) lary (X 14000)
;
: supportive * Alveolar
axis lumen
macrophages alveolar
j ;
E : C. :
elastin capil-
509 ly resolves when the causative organism disappears. Alveolitis of unknown origin, as in IPF, may persist and in such cases usually leads to the fibrosis of "fibroproliferative disease".
SITE OF FIBROSIS The connective matrix of the lung is essential for maintaining its mechanical properties and providing maximal gas-exchange surfaces. Alveolar structures consist of a supportive axis, limited by the epithelial cell layers and composed of interstitial cells and polymorphic fibrillar deposits of collagen and elastin ; and an exchange zone, where alveolar capillaries and epithelial cells are closely associated for easy gas diffusion, being separated only by their basement membranes (Fig 2). The junctions between endothelial cells are leaky, allowing intravascular fluids and molecules to reach the interstitial spaces, whereas tight occluding junctions between alveolar cells prevent the leakage of most substances into the alveolar lumen. Fibrotic changes occuring in alveolar structures will decrease both lung compliance and oxygen diffusion. The degree of functional impairment depends upon both the type of fibrosis and its location within alveolar structures (Fig 3). In IPF, fibrosis is interstitial and diffuse
(Fig 4). All alveolar structures are
involved, resulting in severe clinical impairment due to the loss of gas-exchange units. In sarcoidosis, on the other hand, fibrosis is restricted to the interstitial zones with granulomas and is thus localised. Finally, in COP, intra-alveolar fibrosis is prominent whereas interstitial fibrosis is generally mild (Fig 5).
510
Fig 3 - DIFFERENT
LOCALIZATIONS
OF PULMONARY
FIBROSIS.
3a. Idiopathic pulmonary fibrosis : diffuse fibrotic of alveolar septa. (Masson's trichrome ; X 160)
thickening
Sb. Sarcoidosis : fibrosis restricted to coallescent (arrow) (Masson's trichrome ; X 160)
granulomas
3c. Cryptogenic organizing pneumonitis : Intraalveolar fibrosis (arrow). Thickened alveolar septa due to the presence of inflammatory cells. (Masson's trichrome j X 200)
Fig 4 - FIBROTIC ALVEOLAR S.A. : supportive
SEPTUM : * Alveolar axis (X ¿300)
lumen ; C. : capillary j
511
Fig 5 - Schematic representation of the different locations of pulmonary fibrosis ; A : normal alveolar structure. B : interstitial diffuse fibrosis with widened fibrotic alveolar wall and reduction of air spaces. C : interstitial localized fibrosis respecting most areas of alveolar wall. D : intraalveolar fibrosis without significant impairment of alveolar wall
IDIOPATHIC PULMONARY FIBROSIS IPF is characterized by increasing dyspnea and usually leads to death within a few years. The alveolitis of IPF involves both immune and inflammatory mechanisms (1). Interactions between macrophages, T-lymphocytes, and B-lymphocytes result in the production of immune complexes which activate alveolar macrophages. These release a neutrophil chemotactic factor which recruits circulating neutrophils which in turn release oxidants capable of injuring endothelial and alveolar cells
and components of
the connective matrix. The oxidants may also inactivate alpha-1antitrypsin. The neutrophils may also release proteases such as collagenase which break down the connective matrix (Fig 6).
512
mm
T-LYMPHOCYTES ALVEOLAR MACROPHAGE
Immune
B-LYMPHOCYTES